All researchers, A–Z
Every one of the 929 researchers with a profile in Oliver's mTOR Atlas, listed A to Z by surname, with what each of them contributed to the mTOR field. The grid on Researchers shows the people with three or more studies here; this list leaves nobody out.
A
- Parveez Ahamed Abdul-Azees 1 study Oral biology researcher at the UT Health San Antonio School of Dentistry who works on dental caries, oral biofilms and salivary gland ageing, and first author of the marmoset study of rapamycin and the ageing salivary gland
- Robert T. Abraham 3 studies Co-discovered the mammalian target of rapamycin in 1995, giving it the name mTOR, and showed that it directly phosphorylates the translation repressor 4E-BP1 (PHAS-I)
- Fatima Abrar 1 study First author of a 2026 review on how chemical tags on the autophagy receptor SQSTM1/p62 are linked to neurodegenerative disease
- Monther Abu-Remaileh 5 studies Worked out how to isolate lysosomes fast enough to measure what is inside them, and found that mTOR controls what gets out
- Homa Adle-Biassette 2 studies Neuropathology co-author on two studies of mTOR pathway variants in cortical dysplasia.
- Amany A E Ahmed 1 study Pharmacologist at Helwan University in Cairo who leads animal studies of how existing drugs and natural compounds protect tissues from inflammation, fibrosis and injury
- Rafi Ahmed 1 study Immunologist who studies T-cell and B-cell memory and showed that mTOR is a major regulator of memory CD8 T-cell formation.
- Rose S. Al-Saadi 1 study Doctoral student in Patrick Phillips' lab at the University of Oregon who studies how ageing differs between the sexes, using male C. elegans
- John G. Albeck 2 studies Measures mTORC1, AMPK and other metabolic signals in single living cells, following how they change over minutes and hours
- Dario R. Alessi 3 studies Co-discovered PDK1, the master kinase that switches on Akt and related AGC kinases, and showed that mTORC2 activates the kinase SGK1
- Angela Alexander 1 study First author of the study showing that the DNA-damage kinase ATM also works in the cytoplasm, where it switches on TSC2 in response to reactive oxygen species and so turns mTORC1 down
- Eunus S. Ali 3 studies Showed as a Ben-Sahra-lab postdoc that ERK2 directly activates the purine-synthesis enzyme PFAS, and that mTORC1 increases bicarbonate import through SLC4A7 to fuel nucleotide synthesis. His Kentucky lab studies how growth signals control nucleotide metabolism in cancer
- Siraj M. Ali 5 studies Worked in the Sabatini lab on the papers that discovered raptor, mLST8 and rictor, and on the finding that the rictor-mTOR complex phosphorylates Akt. He later moved into cancer genomics and clinical diagnostics
- David B. Allison 1 study Biostatistician and obesity researcher, long at the University of Alabama at Birmingham and later dean of public health at Indiana University, known for work on nutrition, obesity and research rigour
- Ghada Alsaleh 1 study Senior author studying autophagy and immune-cell ageing; identified a genoprotective mechanism for rapamycin
- Madhanagopal Anandapadamanaban 1 study Structural biologist at the MRC Laboratory of Molecular Biology who solved the structure of the human Rag GTPases bound to mTORC1, showing how amino acids bring mTORC1 to the lysosome
- Sara Ancel 1 study Muscle stem-cell biologist at Sanford Burnham Prebys, trained at Nestle Research and EPFL in Lausanne, who studies why muscle repair fails with age
- Rozalyn M. Anderson 1 study Professor of medicine at the University of Wisconsin-Madison who studies the basic biology of aging and how calorie restriction slows it, and senior author of the 2017 comparison of the two long-running rhesus monkey calorie restriction studies
- Ioannis P. Androulakis 1 study Models how circadian rhythm and nutrient-sensing pathways like mTORC1 stay synchronized
- Martin Hrabě de Angelis 1 study Mouse geneticist who directs large-scale phenotyping of mouse mutants and the German Mouse Clinic, a platform that tests how genes affect health and disease.
- Vladimir N. Anisimov 1 study Russian gerontologist and oncologist who studied the links between ageing and cancer, and whose group tested drugs such as metformin and rapamycin for effects on lifespan and spontaneous tumours in mice
- Sebastian I. Arriola Apelo 2 studies Showed that giving rapamycin intermittently rather than daily lessens its effects on glucose metabolism and the immune system in mice
- Koichi Araki 1 study Immunologist in Rafi Ahmed's group at Emory who discovered that rapamycin improves memory killer T cells, a finding that linked mTOR to vaccine design
- Mariana de Araujo 3 studies Cell biologist in Lukas Huber's group in Innsbruck who solved the crystal structure of the Ragulator (LAMTOR) complex, the lysosomal platform on which mTORC1 is switched on
- Esperanza Arias-Perez 1 study Showed that mTORC2, working with PHLPP1 and Akt at the lysosome, regulates chaperone-mediated autophagy
- John M. Asara 9 studies Mass-spectrometry specialist whose core facility supplied metabolomics and proteomics for several mTOR studies, including measurements of purine, pyrimidine and SAM metabolism downstream of mTORC1.
- Clinton Astle 5 studies Long-time research associate of David Harrison at The Jackson Laboratory, with work on mouse blood stem cells and aging since the 1970s, and a co-author of the Interventions Testing Program papers that showed rapamycin extends mouse lifespan
- Michael B. Atkins 1 study Medical oncologist specialising in kidney cancer and melanoma; led the randomised phase II dose study of temsirolimus (CCI-779) in advanced kidney cancer that supported taking the 25 mg weekly dose forward.
- Steven N. Austad 1 study Comparative biologist of ageing who studies why some species and one sex live longer than others, and who directs the UAB Nathan Shock Center; senior author of a study of how lifelong rapamycin affects health in mice
- Joseph Avruch 6 studies Showed in 1998 that amino acids, not only insulin, are needed for mTOR to activate S6K1 and 4E-BP1. His Massachusetts General Hospital group, with Kazuyoshi Yonezawa's lab in Kobe, then co-discovered raptor in 2002 and found that Rheb binds mTOR directly
- Chetan Aware 1 study Researcher in Ai-Ling Lin's group at the University of Missouri who studies how rapamycin and the gut microbiome affect brain blood flow and metabolism in people and mice at genetic risk of Alzheimer's disease
- Christopher Aylett 2 studies Structural biologist who solved the first cryo-EM architecture of human mTORC1 at ETH Zurich and now leads a cryo-EM group at Imperial College London
- Evandro de Azambuja 1 study Brazilian-born medical oncologist at the Institut Jules Bordet in Brussels who designs and runs large academic breast cancer trials
B
- Wafa B'chir 1 study Metabolism researcher in Vincent Giguère's laboratory at McGill who studies how the nuclear receptor ERR-alpha controls fat handling in the liver, including the fatty liver caused by rapamycin
- Emma L. Baar 2 studies Researcher in Dudley Lamming's group at the University of Wisconsin-Madison who mapped how mTOR signalling changes with age in different mouse tissues and helped test gentler rapamycin dosing schedules
- Reji Babygirija 1 study Researcher in Dudley Lamming's lab at the University of Wisconsin-Madison who studies how restricting single amino acids in the diet affects metabolism, memory and Alzheimer's disease in mice
- Jonathan M. Backer 2 studies Showed that the class III PI 3-kinase hVps34, best known for its role in autophagy, is regulated by nutrients and is needed for amino acids to activate S6 kinase through mTOR, in parallel with George Thomas's group
- Anindya Bagchi 1 study Cancer geneticist and associate professor at Sanford Burnham Prebys who uses chromosome engineering to find cancer genes, known for showing that MYC-amplified cancers depend on the neighbouring gene PVT1
- Peter Bai 1 study Biochemist who studies PARP enzymes, mitochondria and metabolism
- Sara Baldassari 2 studies First author of the 2019 Acta Neuropathologica cohort study on the genetic basis of focal cortical dysplasia.
- Andrea Ballabio 11 studies Discovered that the transcription factor TFEB is a master switch for building lysosomes (SAR2009) and for autophagy. His lab was one of the groups that showed in 2012 that mTORC1 keeps TFEB out of the nucleus from the lysosome surface, and later (2020) that constitutive TFEB activation drives the kidney disease of Birt-Hogg-Dubé syndrome
- Laure Bally-Cuif 1 study Studies how adult neural stem cells in the zebrafish brain move between dormancy and activation
- Nenad Ban 3 studies Structural biologist known for atomic structures of the ribosome and for work on how cells make, fold and sort proteins.
- Sourav Bandyopadhyay 1 study Uses functional genomics, drug screens and proteomics to understand why breast and lung cancers become resistant to drugs, including drugs that target the mTOR pathway.
- Chandrayee Banerjee 1 study Pharmacology researcher at ISF College of Pharmacy in Punjab who writes reviews on signalling pathways and repurposed drugs for multiple sclerosis and other brain diseases
- Christian Bannister 1 study Health data analyst from Craig Currie's group in Cardiff who works with UK primary care records, and first author of the 2014 comparison of survival in people with type 2 diabetes on metformin and people without diabetes
- Liron Bar-Peled 8 studies Showed as a Sabatini-lab graduate student that Ragulator switches the Rag GTPases on, acting as their GEF. He also discovered GATOR1 and GATOR2; GATOR1 switches the Rags off and its genes are mutated in some cancers
- Domagoj Baretić 1 study Structural biologist who, while at the MRC Laboratory of Molecular Biology, solved early cryo-EM structures of Tor and its relatives, and now works on ADP-ribosylation enzymes at Oxford
- Brian G. Barnett 1 study First author of the six-month, placebo-controlled trial of low-dose rapamycin in healthy pet dogs
- Andrzej Bartke 1 study Endocrinologist who showed that Ames dwarf mice, which lack growth hormone because of a single-gene mutation, live much longer than normal mice
- José Baselga 5 studies Breast cancer oncologist who led the BOLERO-2 trial showing that the mTOR inhibitor everolimus added to hormone therapy lengthens progression-free survival
- Helen S. Bateup 2 studies Senior/corresponding author of a 2026 Nature study showing mTORC1 hyperactivity drives cell-autonomous astrocyte reactivity in tuberous sclerosis
- Stefania Battaglioni 1 study Cell biologist in Michael Hall's group at the Biozentrum Basel, first author of a 2022 Cell review that catalogued the direct substrates of mTOR
- Stéphanie Baulac 2 studies Last author of the 2019 Acta Neuropathologica cohort study showing that focal cortical dysplasia type 2 is a mosaic mTORopathy.
- Ralf Baumeister 2 studies Head of the Freiburg department that hosted the Thedieck group during the mTOR network modelling work; co-author on the dynamic mTOR model and the G3BP–TSC study.
- Joseph A. Baur 1 study Biologist of aging at the University of Pennsylvania whose lab showed that rapamycin's harm to glucose control comes from mTORC2 loss and studies how NAD levels shape health
- Johannes Beckers 2 studies Geneticist at Helmholtz Munich and the Technical University of Munich whose group at the Institute of Experimental Genetics runs gene-expression profiling for the German Mouse Clinic
- Pierrick Bedouch 1 study Clinical pharmacist who studies the prevention of adverse drug events and pharmacoepidemiology
- Christian Behrends 1 study Studies autophagy and ubiquitin pathways, and in 2015 reported SLC38A9 as a member of the Rag-Ragulator complex that relays amino acid availability to mTORC1.
- Elena Belousova 2 studies Child neurologist and epilepsy specialist in Moscow who heads a department of psychoneurology and epileptology and has been a principal investigator in international drug trials for tuberous sclerosis complex
- Issam Ben-Sahra 5 studies Showed as a postdoc in Brendan Manning's lab that mTORC1 drives both pyrimidine and purine synthesis, through two different mechanisms. His Northwestern lab has extended this to bicarbonate import, SAM synthesis and ERK control of purine production
- Adriana D. Benavides 1 study Immunologist who worked at UT Health San Antonio and the Children's Hospital of Philadelphia, and a co-author of the first small safety trial of rapamycin in healthy older people
- Steven J. Bensinger 1 study Studies how lipid metabolism shapes innate and adaptive immunity; his lab showed in mice that activated CD8 T cells need SREBP-driven cholesterol and fatty-acid synthesis, switched on through mTOR, in order to grow and divide.
- C. Florian Bentzinger 1 study Muscle stem cell biologist at the Université de Sherbrooke who, as a PhD student in Basel, showed that mTORC1 but not mTORC2 is essential for healthy skeletal muscle
- Seymour Benzer 2 studies Pioneer of fine-structure gene mapping in phage and founder of neurogenetics, whose Drosophila work found the first circadian-rhythm mutants
- Zdenek Berger 1 study Neuroscientist who, in David Rubinsztein's lab in Cambridge, showed that rapamycin-induced autophagy lowers the toxicity of several disease proteins that form clumps, including tau in fruit flies
- Christiane Berger-Schaffitzel 1 study Structural biologist who uses cryo-electron microscopy to study ribosomes and translation machinery; co-senior author of the first cryo-EM structure of yeast TORC2.
- Samuel F. Berkovic 1 study Neurologist who helped establish the genetic causes of many epilepsies, including the discovery that DEPDC5 mutations, which affect the mTORC1 brake GATOR1, cause familial focal epilepsy.
- Alex Berndt 2 studies Protein scientist in Roger Williams' group at the MRC Laboratory of Molecular Biology who helped solve structures of PI3K enzymes and of mTOR and its partners
- Darlene E. Berryman 2 studies Showed that growth hormone reshapes fat tissue in a depot-specific way that links body composition to metabolic aging
- Charles Betz 3 studies Traced mTORC2 to a specific address inside the cell — the mitochondria-ER contact site
- Barbara E. Bierer 1 study Haematologist-oncologist and research-ethics leader whose early lab work helped show how rapamycin acts on immune cells
- Kivanç Birsoy 2 studies Cancer metabolism researcher who trained with Jeffrey Friedman and David Sabatini and now heads the Laboratory of Metabolic Regulation and Genetics at The Rockefeller University, using genetic screens to find how cancer cells rewire their metabolism
- John J. Bissler 2 studies Led the first clinical trial showing that the mTOR inhibitor sirolimus shrinks kidney angiomyolipomas in tuberous sclerosis, and the EXIST-2 trial of everolimus for the same tumours
- Alessandro Bitto 1 study Showed that a short, three-month course of rapamycin in middle-aged mice can extend lifespan and improve healthspan
- Ivana Bjedov 1 study Studies DNA repair and protein synthesis in ageing; showed that rapamycin extends lifespan in fruit flies
- T. Keith Blackwell 1 study Geneticist who uses the worm C. elegans to study how the SKN-1/Nrf stress-response factor, insulin signaling and TOR shape stress resistance and lifespan.
- Mikhail V. Blagosklonny 3 studies Proposed the hyperfunction theory of ageing: TOR signalling that builds a young body never fully switches off, and drives its ageing instead
- Helen M. Blau 1 study Stem cell biologist known for work on muscle stem cells, regeneration, cell reprogramming and rejuvenation, including how aging muscle loses strength.
- John Blenis 14 studies Showed early on that rapamycin blocks S6 kinase, then worked out how mTORC1 drives cell growth through its two main translation targets, S6K1 and 4E-BP1. His lab also found, in parallel with the Sabatini lab, that mTORC1 phosphorylates Grb10, a feedback brake on insulin signalling
- Su Bo 1 study Cardiothoracic surgery researcher in Xiangyang who tests natural compounds against lung cancer cells, including gambogic acid acting on the AKT and mTOR pathway
- Natalia Bobok 1 study Physician-scientist and founder of a Swiss longevity/skincare company; author of a 2026 review situating mTOR as an integrative signaling hub across the hallmarks of aging
- Sue C. Bodine 2 studies Showed that turning on the Akt-mTOR pathway is enough, by itself, to make skeletal muscle grow and to stop it from wasting away
- Daniel Boehringer 3 studies Electron microscopy specialist at ETH Zurich whose cryo-EM work underpins the Atlas structures of human mTORC1 and mTORC2
- Timothy A. Bolger 1 study Studies how RNA helicases such as yeast Ded1 and human DDX3X control protein production under stress, including after TORC1 inhibition.
- Grégory Bonfils 1 study First author of the yeast study proposing that leucyl-tRNA synthetase passes the leucine signal to TORC1 by binding the Rag GTPase Gtr1
- Johannes L. (Hans) Bos 2 studies Cancer biologist known for work on Ras mutations and for the small GTPase Rap1 and its activator Epac, a cAMP-regulated switch for cell adhesion
- Nathalie Bouquier 1 study Built AIMTOR, a glowing biosensor that lets researchers watch mTOR activity move around inside a living cell in real time
- Lara M. Boyle 2 studies Research assistant at Boston Children's Hospital who co-authored both studies linking mTOR to the clock protein BMAL1, including the tuberous sclerosis study where she was second author.
- Edward J. Brignole 3 studies Research scientist who directs the cryo-electron microscopy facility at MIT.nano and whose cryo-EM work helped solve the structures of GATOR1, GATOR2 and Raptor docked on the Rag GTPases for the Sabatini lab
- Laura Brohée 2 studies Cell biologist who studied how lipid metabolism and the lysosome feed into mTORC1, first at the University of Liège and then at the Max Planck Institute for Biology of Ageing in Cologne
- Eric J. Brown 1 study Co-discoverer of mTOR: as first author he isolated the mammalian protein bound by the rapamycin-FKBP12 complex (FRAP) and cloned its gene in 1994.
- Holly M. Brown-Borg 1 study Physiologist who measures how reduced growth-hormone signalling changes lifespan and what keeps long-lived mutant mice healthy
- James Brugarolas 3 studies First author of the 2004 study showing that hypoxia switches off mTOR through REDD1 and the TSC1/TSC2 complex; now directs a kidney cancer research program studying signalling and resistance to targeted drugs.
- Anne Brunet 1 study Showed that Akt directly phosphorylates and controls FOXO, the transcription-factor switch linking insulin/IGF-1 signaling to lifespan
- Andrei V. Budanov 3 studies Helped identify the Sestrins as stress-induced proteins and was among the groups that showed they inhibit mTORC1 through the GATOR complex, a brake that protects against age-related disease
- Klemens Budde 1 study Kidney and transplant physician who took part as an investigator in the EXIST-2 trial of everolimus for kidney tumours in tuberous sclerosis and LAM; clinician-investigator rather than a bench mTOR researcher.
- Howard A Burris 2 studies Medical oncologist who led the Sarah Cannon Research Institute in Nashville as President and Chief Medical Officer, has run hundreds of early-phase cancer drug trials, including the first trial of the mTORC1-selective inhibitor RMC-5552, and was ASCO President in 2019–2020
- Sabrina Büttner 2 studies Studies how organelles communicate inside cells and how that communication breaks down with age, and contributed to the Graz studies showing that spermidine extends lifespan by inducing autophagy
- Maya P. Byfield 2 studies Showed as first author that the lipid kinase hVps34 is regulated by nutrients and is needed for amino acids to activate S6 kinase through mTOR, in parallel with a study from George Thomas's group
C
- Rafael de Cabo 1 study Aging researcher at the US National Institute on Aging who has studied calorie restriction, fasting and drugs that mimic them in mice and rhesus monkeys, including the long-running NIA monkey study
- Antonella Caccamo 1 study Neuroscientist who, with Salvatore Oddo, showed in Alzheimer's model mice that amyloid-beta and mTOR feed each other in a loop that rapamycin can break
- Alessia Calcagnì 3 studies TIGEM researcher on the TFEB/TFE3 side of mTORC1 signalling; co-author on the lysosomal stress route to TFEB activation and on mouse models separating mTORC1 from TFEB/TFE3 in kidney cysts and tumours.
- Judith Campisi 1 study Pioneer of research on cellular senescence and the senescence-associated secretory phenotype (SASP); her 2015 paper showed that mTOR drives the inflammatory SASP.
- Mario Campone 2 studies Breast cancer oncologist and general director of the Institut de Cancérologie de l'Ouest, a co-investigator on the BOLERO-2 trial that brought everolimus into breast cancer care
- Lewis C. Cantley 12 studies Co-discovered PI3K, the pathway that feeds into mTOR from growth factors
- Doreen A. Cantrell 1 study Studies how signaling and metabolism control T-cell fate, including how amino-acid uptake and mTORC1 steer T-cell differentiation.
- Peng Cao 1 study Wound-repair researcher at the Burn and Trauma Treatment Center in Wuxi who tests natural compounds against scarring and diabetic wound inflammation
- Zheng Cao 1 study Veterinary toxicologist at Northeast Agricultural University in Harbin whose group studies how pollutants and food toxins damage the kidney, liver and gut in mice
- Zhi-Lie Cao 1 study Urologist in Zhejiang who works with colleagues on inherited endocrine tumour syndromes and wrote a review re-examining how FLCN loss changes mTORC1 signalling in Birt-Hogg-Dube syndrome
- Jaume Capdevila 2 studies Medical oncologist specialising in neuroendocrine and endocrine tumours
- Steven D. Cappell 1 study Studies how single cells commit to dividing; showed that mTOR briefly switches off the APC/C to give cells a pulse of glycolysis at cell cycle entry
- Manuel Carcao 1 study Paediatric haematologist specialising in bleeding disorders
- David Carling 1 study Biochemist who heads the Cellular Stress group at the MRC Laboratory of Medical Sciences in London and has spent decades working out how the energy sensor AMPK is switched on and what it controls
- Didac Carmona-Gutierrez 2 studies Studies how cell death and autophagy shape ageing at the University of Graz, and contributed to the studies showing that spermidine extends lifespan through autophagy
- Arkaitz Carracedo 1 study Cancer biologist who, as first author in 2008, showed that blocking mTORC1 can switch on the MAPK pathway through a PI3K-dependent feedback loop.
- Bernadette Carroll 3 studies First author of the study showing why mTORC1 stays switched on in senescent cells, and co-author on G3BP–TSC and senescence-mitophagy work; her own lab studies how nutrient sensing breaks down in ageing cells.
- James A. Carson 1 study Muscle physiologist studying cancer-associated cachexia and how chemotherapy and exercise remodel skeletal-muscle metabolism
- Brian M. Castellano 1 study Cell biologist who, in Roberto Zoncu's lab at UC Berkeley, showed that cholesterol inside the lysosome switches on mTORC1 through the SLC38A9 and NPC1 proteins
- Rogerio M Castilho 1 study Dentist and cell biologist who showed, as a postdoc at the US National Institutes of Health, that Wnt signalling wears out skin stem cells through mTOR and that rapamycin can prevent it, and whose University of Michigan lab now studies how histone marks control epithelial healing and treatment resistance in head and neck cancer
- Jamie H. D. Cate 1 study Structural and molecular biologist who studies how ribosomes and the initiation factor eIF3 control which mRNAs are translated into protein.
- Francesco Cecconi 1 study Discovered AMBRA1, a regulator of autophagy, and showed how mTOR restrains autophagy by acting on AMBRA1 and ULK1.
- Madi Y. Cissé 2 studies Research associate in the Manning lab and co-author on the two 2026 mouse studies showing which feeding signals switch on mTORC1 in liver and in skeletal muscle.
- Jon Clardy 1 study Chemist who solved the crystal structure of the FKBP12-rapamycin-FRB (mTOR) complex, showing how rapamycin acts as a molecular glue between two proteins.
- Amanda Erickson Coleman 1 study Veterinary cardiologist and first author of the design paper for TRIAD, the lifespan trial of rapamycin in pet dogs
- Kendall J. Condon 4 studies Ran genome-wide CRISPR screens revealing how mitochondrial stress signals to mTORC1
- Yann Cormerais 2 studies Research scientist in the Manning lab who works on how PI3K–AKT–TSC2 signalling controls mTORC1 in living tissues, using mouse models in which TSC2 cannot be phosphorylated by AKT.
- Marion Cornu 2 studies Physiologist from Michael Hall's Basel lab who showed in mice that mTORC1 in the liver controls body temperature, movement and fat metabolism through the hormone FGF21
- Michael N. Corradetti 1 study As an MD-PhD student at the University of Michigan, was first author on the 2004 study linking the LKB1 tumour suppressor to TSC2 through AMPK. He is now a radiation oncologist
- Clara Correia-Melo 1 study Ageing biologist who showed with João Passos in Newcastle that rapamycin can improve healthspan in mice without lowering inflammation, and later studied metabolite sharing between cells in Markus Ralser's lab
- Mauro Costa-Mattioli 2 studies Neuroscientist who studies how mTOR signaling and protein synthesis control learning, memory and brain function, including the role of mTORC2 in long-term memory.
- Sabina Cosulich 1 study Cancer drug discovery scientist at AstraZeneca whose work spans PI3K and mTOR pathway inhibitors, PARP1 inhibitors and phosphoinositide lipid signalling
- Daniela Cota 1 study Studies how the brain senses nutrients and hormones to control food intake and body weight; as a postdoc in Cincinnati she was first author of the rat study that tied hypothalamic mTOR signalling to food intake and leptin action.
- Douglas F. Covey 2 studies Medicinal chemist and Andrew C and Barbara B Taylor Distinguished Professor of Psychiatry at Washington University in St. Louis who designs synthetic steroids and sterols to study neurosteroids, GABA-A receptors and cholesterol sensing, including in two Atlas studies on cholesterol and mTORC1
- Gerald R. Crabtree 2 studies Helped define the calcineurin-NFAT pathway behind cyclosporine and FK506, and showed in 1992 that rapamycin blocks IL-2 activation of p70 S6 kinase.
- Kate E. Creevy 3 studies Runs the veterinary side of the Dog Aging Project and leads TRIAD, the trial testing whether rapamycin extends lifespan in pet dogs
- Sean P. Cregan 1 study Studies the molecular pathways that trigger neuron death, aiming to find drug targets that protect neurons in stroke and in diseases such as Parkinson, Alzheimer and Huntington.
- Kerry R. Crone 1 study Pediatric neurosurgeon in Cincinnati; senior author of the small case series in which oral rapamycin shrank brain astrocytomas in patients with tuberous sclerosis complex.
- Ana Maria Cuervo 1 study Worked out much of the machinery of chaperone-mediated autophagy, a pathway first described in Fred Dice's laboratory, and showed it declines with age
- Xiaoli Cui 1 study Pharmacologist at Beihua University who studies how plant-derived compounds protect the kidney and heart from damage caused by high blood pressure in mice
- Zhicheng Cui 2 studies Structural biologist who solved cryo-EM structures of the mTORC1–TFEB–Rag–Ragulator megacomplex and of mTORC1 switched on by RHEB and the Rags on a lipid membrane.
- Nicole E. Cummings 2 studies Graduate researcher in Dudley Lamming's lab at the University of Wisconsin-Madison and first author of a 2017 study reporting that eating fewer branched-chain amino acids restores metabolic health
- John T. Cunningham 1 study Cancer biologist who showed in Puigserver's lab at Dana-Farber that mTOR controls mitochondrial activity, later worked on protein synthesis and nucleotide metabolism in cancer in Davide Ruggero's lab at UCSF, and now works at the University of Cincinnati
- Paolo Curatolo 1 study Child neurologist at Tor Vergata University in Rome who has spent much of a long career on tuberous sclerosis complex, the genetic disease of overactive mTOR, with a focus on epilepsy and brain development in children
- Craig Currie 1 study Pharmacoepidemiologist at Cardiff University who uses large UK primary care databases to study diabetes treatments and their long-term outcomes, and senior author of the 2014 metformin survival study
- Nadine Cybulski 2 studies Cell biologist from Michael Hall's Basel lab who showed that mTORC2 in fat tissue helps control how big the whole body grows
- Ronjon Chakraverty 1 study Haematologist and transplant immunologist who studies why T cell immunotherapies succeed or fail, including how tuning T cell metabolism through mTORC1 changes their function.
- Edmond Y. W. Chan 1 study Studies how nutrient-sensing kinases, including ULK1, mTORC1 and AMPK, control autophagy and mitochondrial stress responses; in Sharon Tooze's lab he helped identify ULK1 as a kinase needed for starvation-induced autophagy in human cells.
- Sze Ham Chan 2 studies Researcher at the Whitehead Institute who contributed to studies of lysosome contents, nutrient sensing and cancer metabolism, mostly from David Sabatini's lab
- Lynne Chantranupong 12 studies Showed as a Sabatini-lab graduate student that the Sestrins act through GATOR2 to regulate amino-acid signalling to mTORC1. She then discovered the CASTOR proteins, the cell's arginine sensors for the pathway
- Chong Chen 2 studies Showed that blood stem cells need TSC to keep mTOR in check in order to stay dormant and self-renew, and that rapamycin restores the function of aged blood stem cells in mice
- Kewei Chen 1 study Researcher in plastic surgery at Wenzhou Medical University and first author of a mouse study on engineered stem-cell exosomes that speed wound healing by changing fibroblast metabolism
- Sheng Chen 1 study Orthopaedic researcher who contributed to a study showing that the plant compound corilagin protects joint cartilage by calming inflammation and restoring autophagy
- Shiwen Chen 1 study Aquaculture physiologist studying why the largemouth bass, a carnivorous fish, tolerates dietary carbohydrate so poorly
- Walter W. Chen 1 study Co-author of the 2017 Cell paper showing that SLC38A9 releases essential amino acids from lysosomes to switch on mTORC1
- Wanying Chen 1 study Member of a Wenzhou wound-healing and adipose-stem-cell research group who contributed to a study of FGF21-modified exosomes that promote wound healing through AMPK–mTOR
- Wei Chen 1 study Showed that IGF2BP3-mediated m6A modification of OLR1 mRNA helps colorectal cancer evade CD8+ T cells through the PI3K/AKT/mTOR pathway
- Wei-Ying Chen 1 study Urologist at Taizhou Hospital in Zhejiang and senior author of a review on why FLCN loss affects mTORC1 selectively in Birt-Hogg-Dube syndrome
- Xianglong Chen 1 study Orthopedic researcher at Union Hospital, Wuhan, and first author of a 2026 study that found a new route by which failing autophagy switches on mTORC1 and drives spinal disc degeneration
- Xizi Chen 1 study Structural biologist in Yanhui Xu's group at Fudan University who was first author of the 2018 cryo-EM structure of human mTORC2 and co-first author of an earlier structure of human mTORC1
- Hongbo Chi 3 studies Showed that regulatory T cells need mTORC1 signalling to fuel their suppressive function, and studies how mTOR-driven metabolism steers T-cell fate
- Mathilde Chipaux 2 studies Paediatric neurosurgery co-author on two studies of mTOR pathway variants in cortical dysplasia.
- Yongwon Choi 1 study Immunologist who studies TRAF6 and RANKL (TRANCE) signalling at the junction of the immune and skeletal systems; senior author of the study linking TRAF6 and fatty acid oxidation to CD8 T-cell memory
- Edward T. Chouchani 1 study Senior/corresponding author on a bioRxiv preprint showing dietary restriction licenses autophagy through oxidation of a single cysteine (Cys19) on the core autophagy protein ATG5
- Christine M. Chresta 1 study Cancer biologist at AstraZeneca who led the preclinical description of AZD8055, one of the first ATP-competitive mTOR kinase inhibitors to reach clinical testing
- Christina Lee Chung 1 study Dermatologist specialising in skin disease of organ transplant recipients, and first author of a small randomised trial showing that topical rapamycin lowers a senescence marker in aging human skin
- Won-Suk Chung 1 study Neuroscientist who studies how glial cells (astrocytes and microglia) shape synapses, and senior author of the 2026 study linking neuronal ERBB4 and mTOR signaling to early Alzheimer's disease changes in mice
D
- Agnieszka Dąbkowska 1 study Leukemia researcher in Warsaw who works on new drug combinations for B-cell acute lymphoblastic leukemia, including mTORC1 inhibitors that make leukemia cells easier targets for anti-CD20 antibodies
- Lufeng Dan 1 study Yeast geneticist at Chengdu University who studies reversible mutations that let cells switch drug resistance on and off, using rapamycin resistance in fission yeast as the model
- Fred C. Davis 2 studies Circadian biologist from Northeastern University who brought expertise on the brain's master clock to two studies linking mTOR and the clock protein BMAL1.
- Oliver B. Davis 2 studies Cell biologist who did a PhD in Roberto Zoncu's lab at UC Berkeley on how lysosomal cholesterol controls mTORC1, and first author of a 2020 study proposing NPC1-mTORC1 signalling as a drug target in Niemann-Pick type C disease
- Jayanta Debnath 1 study Physician-scientist who studies how autophagy - the cell's self-digestion system - keeps epithelial tissue healthy and how tumours hijack it
- Ines Deleu 2 studies Medical oncologist in Sint-Niklaas, Belgium, who enrolled patients in international breast cancer drug trials, including the BOLERO-2 trial of everolimus
- Greg M. Delgoffe 3 studies Showed as a graduate student in Jonathan Powell's lab that T cells lacking mTOR become regulatory rather than effector T cells, and that mTORC1 and mTORC2 steer different helper-T-cell fates
- Constantinos Demetriades 7 studies Showed as a postdoc in Aurelio Teleman's lab that starvation and other stresses pull TSC2 to the lysosome to switch mTORC1 off. His group, at the Max Planck Institute for Biology of Ageing in Cologne from 2017 and at ERIBA in Groningen since 2025, studies how cells sense nutrients and stress through mTORC1 and how this changes with age
- Zoya N Demidenko 1 study First author of the 2009 Cell Cycle study showing that rapamycin slows cellular senescence.
- Aykut Demir 1 study Leukaemia researcher at Heidelberg University and first author of the 2026 study showing that the enzyme IDH3 keeps acute myeloid leukaemia stem cells metabolically fit and resistant to venetoclax
- Matthew D. Demmings 1 study Neuroscience researcher in Sean Cregan's lab at Western University who showed that chronic ATF4 stress signalling shuts down mTOR and kills dopamine neurons in models of Parkinson's disease
- Jörn Dengjel 3 studies Mass-spectrometry proteomics specialist in autophagy and protein homeostasis; co-author on the TBK1/ULK1–TFEB lysosomal stress pathway and on the spermidine lifespan and cardioprotection study.
- Onur Deniz 1 study Doctoral researcher in Ville Hietakangas's nutrient-sensing group in Helsinki, and first author of the fruit-fly study that found Spalt-related to be a stress-activated brake on mTORC1-driven growth
- Patrick B. Dennis 1 study As a postdoc in George Thomas's lab at the Friedrich Miescher Institute, was first author on the 2001 study proposing that mTOR responds to cellular ATP levels independently of amino acids
- Vojo Deretic 1 study Studies how autophagy shapes infection, immunity and inflammation, including early work showing that autophagy restricts Mycobacterium tuberculosis, and how galectins and TRIM proteins control mTOR and AMPK.
- M. Phillip DeYoung 1 study As a research fellow in Leif Ellisen's lab, was first author on the 2008 study showing that hypoxia switches off mTORC1 through REDD1 releasing TSC2 from 14-3-3 proteins
- Vivian Diaz 2 studies Aging researcher at the Barshop Institute in San Antonio who has worked for more than a decade on the mouse lifespan studies behind rapamycin's reputation as an anti-aging drug, including the Interventions Testing Program
- Leanne M. Dibbens 1 study Epilepsy geneticist at the University of South Australia who found that mutations in DEPDC5, part of the GATOR1 brake on mTORC1, cause familial focal epilepsy
- Christian C. Dibble 4 studies Identified TBC1D7 as the third subunit of the TSC complex that controls mTORC1, as a Manning-lab graduate student. His lab at Beth Israel Deaconess studies how PI3K signalling and nutrient supply are integrated to control mTORC1 and cell metabolism
- Wen-Xing Ding 1 study Studies autophagy and mitophagy in liver injury and the roles of Nrf2 and mTOR in liver disease and cancer
- N. Valerio Dorrello 1 study Pediatric critical care physician-scientist at Columbia University whose training in Michele Pagano's lab at NYU showed how S6K1 removes the translation brake PDCD4, and who now works on repairing injured children's lungs
- Monica Driscoll 1 study Studies the biology of ageing in the roundworm C. elegans, including interventions that extend healthspan and the mechanisms that protect neurons from damage.
- Micah J. Drummond 1 study Muscle physiologist at the University of Utah who studies why older muscle wastes during inactivity and recovers poorly, and who showed that mTORC1 drives part of the protein-building response to exercise in humans
- Xingrong Du 1 study Studies how cellular metabolism and signaling shape the function of T cells, regulatory T cells and dendritic cells in tumor immunity, autoimmunity and immunodeficiency.
- Ronald S. Duman 1 study Psychiatric neuroscientist who showed that ketamine's rapid antidepressant effect depends on mTOR signaling and the growth of new synapses in the prefrontal cortex.
- Raúl V. Durán 1 study Cell biologist who showed that glutamine breakdown feeds amino acid signalling to mTORC1, and who now leads research on mTOR, glutamine metabolism and cancer at CABIMER in Seville
- Silvana Duran-Ortiz 1 study Researcher in John Kopchick's group at Ohio University who studies how switching off growth hormone action, even in middle age, lengthens life in mice
- Katrin Düvel 1 study First author of the study showing that mTORC1 switches on a metabolic gene program through HIF1α and SREBP, driving glycolysis, the pentose phosphate pathway and lipid synthesis
E
- Bruce A. Edgar 1 study A Drosophila geneticist who studies how cells and tissues control their growth, including the role of Rheb in the insulin/TOR network.
- Alejo Efeyan 3 studies Showed that the Rag GTPases, which relay amino-acid signals to mTORC1, are a life-or-death switch for newborn mice surviving the fast before their first feeding
- Daniel F. Egan 2 studies Showed as first author that AMPK directly phosphorylates ULK1, linking low cellular energy to autophagy and mitophagy, and contributed to the finding that AMPK brakes mTORC1 by phosphorylating raptor
- Dan Ehninger 2 studies Showed that rapamycin reverses learning deficits in adult mice carrying a tuberous sclerosis mutation, and later tested carefully whether rapamycin's lifespan effect reflects a true slowing of ageing
- Tobias Eisenberg 2 studies Showed as first author that the dietary polyamine spermidine extends lifespan by inducing autophagy, and later that it protects the heart in an autophagy-dependent way
- Leif W. Ellisen 1 study Physician-scientist whose lab studies REDD1, a stress-induced inhibitor of mTORC1, and showed how hypoxia uses REDD1 to release TSC2 from 14-3-3 proteins
- Mahmoud Elshal 1 study Pharmacologist at Mansoura University who tests whether existing drugs can protect the brain, liver and other organs in rodent models of disease
- Hediye Erdjument-Bromage 5 studies Ran the mass-spectrometry analyses in Paul Tempst's lab at Memorial Sloan Kettering that identified the unknown proteins in the raptor, mLST8 and rictor purifications, and contributed the same approach to work on how ERK inactivates TSC2
- Alessandra Esposito 4 studies Lysosomal signalling and TFEB regulation
- Simone Evans 1 study Neuroscience researcher at Dartmouth who studies how growth signals shape the skeleton of sensory nerve fibres, and first author of work showing that PTEN acts on microtubules through mTORC2 rather than mTORC1
F
- Valeria Facchinetti 1 study First author of the study showing that mTORC2 phosphorylates the turn motif of Akt and conventional PKC as the proteins are made, which helps them fold and stay stable
- Wenjun Fan 1 study Cancer biologist in Marikki Laiho's lab at Johns Hopkins who studies ribosome production as a weak point of cancer cells, and who showed how mTOR inhibition helps cells survive when ribosomes run short
- Elias Bou Farhat 1 study First author of the 2026 JCI Insight paper on a TSC2-mutant minipig model of cardiac rhabdomyoma.
- Morris E. Feldman 1 study Chemical biologist who, in the Shokat lab at UCSF, introduced PP242 and the TORKinib class of drugs that block mTOR's active site and reach the outputs rapamycin misses
- Hongxuan Feng 1 study Neurologist at Suzhou Municipal Hospital and senior author of a 2026 stroke study proposing PIP4K2A as a protector of brain tissue through AKT/mTOR signalling and autophagy
- Xiaodong Feng 1 study Researcher at the State Key Laboratory of Oral Diseases in Chengdu whose group studies how cells in the mouth respond to stress, from chemotherapy tolerance in oral cancer to inflammation in gum disease
- Shawn M. Ferguson 2 studies Showed that mTORC1 phosphorylates TFEB to keep the lysosome-building program switched off, and that folliculin is required at the lysosome for amino acids to recruit and activate mTORC1
- Stephanie A. Fernandes 3 studies First author of the study showing that lysosomal and cytoplasmic pools of mTORC1 respond to different amino acid sources and phosphorylate different substrates.
- Elizabeth Fernandez 3 studies Aging researcher at the Barshop Institute in San Antonio who has worked on rapamycin studies in mice and common marmosets, including the NIA Interventions Testing Program
- Marco Ferniani 1 study First author of the study showing mTORC1 hyperactivation, not TFEB/TFE3 activity itself, is the primary driver of kidney cystogenesis and tumorigenesis in mouse models of Birt-Hogg-Dubé and Tuberous Sclerosis
- Stefan Feske 1 study Senior author identifying intracellular pH regulation via SLC4A7/NBCn1 as required for mTORC1 activity and antibody-secreting cell differentiation
- Stanley Fields 2 studies Technology-driven geneticist whose yeast screens helped show that lowering TOR signaling extends chronological lifespan in yeast
- Gianluca Figlia 2 studies Cell biologist who studied how mTORC1 senses nutrients in Aurelio Teleman's group at the German Cancer Research Center, including the finding that glutamine is sensed through the kinase GCN2, and who now works at the Institute of Neuropathology in Aachen
- Peter M Finan 2 studies Biochemist and drug-discovery leader who started the PI 3-kinase drug discovery program at Novartis and ran its Developmental and Molecular Pathways group in Cambridge, Massachusetts, before moving into life-science venture investing
- Greg M. Findlay 1 study Uses pluripotent stem cells to study how faulty signalling by protein kinases causes intellectual disability
- Diane C. Fingar 3 studies Studies how mTORC1 and mTORC2 are regulated, especially through site-specific phosphorylation
- Toren Finkel 2 studies Studies the biology of aging, including how mTOR levels and mitochondria influence lifespan and healthspan in mammals.
- Malgorzata Firczuk 1 study Immunologist in Warsaw who leads research on the weak points of B-cell leukemias and lymphomas, from the thioredoxin antioxidant system to combinations of mTORC1 inhibitors with antibody drugs
- Kathleen E. Fischer 1 study Comparative biologist of ageing who studies why ageing rates differ between sexes, strains and species, and who led a long-term study of how lifelong rapamycin affects health measures in mice
- William E Fitzsimmons 1 study Last and corresponding author of the 2026 GeroScience registry study of rapamycin and survival in kidney transplant recipients.
- Kevin Flurkey 4 studies Biologist of aging at The Jackson Laboratory who has studied mouse lifespan and hormones since the early 1980s and co-authored the Interventions Testing Program papers on rapamycin
- James M. Flynn 1 study Aging researcher from Simon Melov's lab at the Buck Institute who showed that a short course of rapamycin late in life can partly reverse heart aging in mice
- Wilson C. Fok 1 study Biologist of aging who, in Viviana Pérez's group in San Antonio, compared rapamycin with dietary restriction in mouse liver and showed that rapamycin's lifespan gain comes with large changes in liver gene activity
- Amanda C. Foks 1 study Studies how the immune system drives atherosclerosis and how it changes with age, including how rapamycin reshapes immune cells in aged atherosclerotic mice.
- Luigi Fontana 1 study Studies how diet and calorie restriction affect human ageing and metabolic health, and co-wrote a widely cited Science review linking dietary restriction to nutrient-sensing pathways such as mTOR
- Marc Foretz 1 study Researcher at the Institut Cochin in Paris who studies how the liver controls sugar and fat, and whose 2010 work showed that metformin can lower liver glucose output without AMPK
- Antoine Fraissenon 1 study Paediatric radiologist who works on vascular anomalies and PIK3CA-related overgrowth
- David N. Franz 5 studies Led the EXIST-1 trial showing that the mTOR inhibitor everolimus shrinks the brain tumours (SEGAs) of tuberous sclerosis, and helped run the first sirolimus trial for its kidney tumours
- Elizaveta Freinkman 2 studies Chemist and mass-spectrometry specialist at the Whitehead Institute who measured metabolites for many studies of nutrient sensing and cancer metabolism, including the lysosome amino acid work behind two Atlas papers
- Antonio Carlos de Freitas 1 study Geneticist who studies human papillomavirus, HPV vaccines and diagnostics, and links between HPV and breast and lung cancer
- Jacqueline A. French 1 study Epilepsy clinical-trial specialist; first author of EXIST-3, the placebo-controlled phase 3 trial in which everolimus reduced treatment-resistant seizures in tuberous sclerosis complex.
- Maria A Frias 1 study Cancer biologist who did her doctoral research on mTORC2 in David Sabatini's lab and now teaches biology at St. Francis College in Brooklyn, while continuing work with David Foster on how the lipid phosphatidic acid controls mTOR
- Michael D. Frost 2 studies Co-investigator on the EXIST-1 and EXIST-2 trials showing that the mTOR inhibitor everolimus shrinks tuberous sclerosis tumours in the brain and kidney
- David A. Fruman 1 study Immunologist and cancer biologist who studies PI3K and mTOR signaling in lymphocytes and leukemia cells and the drugs that target them.
- Helmut Fuchs 2 studies Scientific and technical head of the German Mouse Clinic at Helmholtz Munich, the standardised many-organ testing platform for mouse models that Fuchs helped build
- Keishi Fujio 1 study Rheumatologist and immunologist who studies how self-tolerance breaks down in autoimmune disease, including lupus, and how nutrient sensing by CASTOR1 shapes B-cell responses.
G
- Valérie Gailus-Durner 2 studies Biochemist who co-founded the German Mouse Clinic at Helmholtz Munich and leads it as scientific head, running standardised testing of mouse models across many organ systems
- Veronica Galvan 2 studies Led mouse studies showing that rapamycin prevents Alzheimer's-like memory loss and amyloid build-up, and improves learning in normally ageing mice
- Steven J. Gamblin 1 study Structural biologist and Fellow of the Royal Society who solved the crystal structure of active mammalian AMPK, the cell's energy sensor and the main counterweight to mTORC1, and who now directs the scientific platforms of the Francis Crick Institute
- Xiaoqing Gan 1 study Biochemist at Fudan University who showed as a Yale postdoc that the lipid messenger PIP3 directly switches on mTORC2, and who now studies Wnt and mTORC2 signalling in metabolism
- Ian G. Ganley 1 study Showed, in one of three 2009 studies (alongside the Mizushima and Kim laboratories), that the ULK1–ATG13–FIP200 complex relays mTOR signalling to start autophagy, and studies how cells select damaged mitochondria for destruction
- Ke Gao 1 study Urology researcher at Xi'an People's Hospital and first author of a 2026 multicentre study showing that the fat content of TSC kidney tumours predicts how well they shrink on everolimus
- Peng Gao 4 studies Directs the Northwestern metabolomics core that supplied mass-spectrometry metabolite measurements for three Ben-Sahra lab studies on how mTORC1 and ERK signalling drive nucleotide and SAM synthesis.
- Xinsheng Gao 1 study Geneticist who, in Duojia Pan's lab, used fruit flies and mammalian cells to show that the tumour suppressors Tsc1 and Tsc2 restrain TOR signalling and make it sensitive to amino acids
- Attila Garami 1 study First author of the 2003 study, from George Thomas's group at the Friedrich Miescher Institute, showing that insulin switches on Rheb and that the TSC1-TSC2 complex switches it off
- Juan M. García-Martínez 2 studies Discovered mTORC2 activates SGK1 and co-developed Ku-0063794, one of the first selective ATP-competitive mTOR inhibitors
- Roger Geiger 1 study Studies how metabolism regulates T-cell responses against tumours; first author of the study showing that raising L-arginine shifts human T cells towards oxidative metabolism and longer survival, an effect the authors found to be independent of mTOR.
- Vincent Giguère 1 study Studies how nuclear receptors, especially the estrogen-related receptors (ERRs), control energy metabolism, and showed that mTOR and ERRα share target genes involved in lipid and TCA-cycle metabolism
- Brooke Gile 1 study Researcher in Simmaron Research's laboratory in Milwaukee who works on low-dose rapamycin as a possible treatment for ME/CFS and led the 2026 analysis of its effects on purine metabolism
- Anne-Claude Gingras 2 studies Showed in 1999 that mTOR phosphorylates 4E-BP1 in a priming two-step mechanism, and now leads work on interaction proteomics (including BioID) that maps how cells read signals such as mTORC1
- Miriam Ginzberg 1 study Helped build a way to read a signal's history from still images of fixed cells, then used it to catch mTORC1's fingerprint on Akt
- Christos G. Gkogkas 1 study Studies how protein synthesis is controlled in the brain; first author of the mouse study linking loss of the translational repressor 4E-BP2, downstream of mTORC1, to autism-like behaviour through increased neuroligin translation.
- David J. Glass 2 studies Muscle biologist and Regeneron vice president for ageing research, member of the US National Academy of Sciences, who helped discover the muscle-wasting enzymes MuRF1 and MAFbx and co-authored the first trials of low-dose mTOR inhibition in older people
- Michael Gnant 2 studies Surgical oncologist and breast cancer trialist, Professor of Surgery at the Medical University of Vienna and President of the Austrian Breast and Colorectal Cancer Study Group, and a co-author of BOLERO-2, the trial that brought the mTOR inhibitor everolimus into breast cancer treatment
- Deborah C. I. Goberdhan 1 study Oxford cell biologist who studies how amino acid transporters and the cell's secretory compartments control growth signalling, often using the fruit fly, and who argued that intracellular transporters mark where mTORC1 is switched on
- Peter Gollwitzer 3 studies First author of the 'Rag dimer code' study showing that the four Rag GTPase paralogues are not interchangeable: RagC/D sets substrate choice and RagA/B sets the response to amino acid withdrawal.
- Tamir Gonen 1 study Determines the 3D structures of membrane proteins and pioneered microcrystal electron diffraction (MicroED); in the mTOR field he solved the structure of the lysosomal arginine transporter SLC38A9.
- Hani Goodarzi 2 studies Systems biologist at UCSF and the Arc Institute who combines computation and experiments to find hidden gene-regulation programs that drive cancer, and a co-author of two Atlas studies on mTORC1 in drug-resistant cancers
- Claire Goul 1 study Cell biologist who did graduate work in Roberto Zoncu's lab at UC Berkeley on lysosomes and mTORC1, first author of a major review of how mTORC1 senses nutrients and of a 2026 Nature study on how damaged lysosomes are repaired, now a scientist at CZ Biohub
- Brian C. Grabiner 3 studies Catalogued cancer-associated MTOR mutations and showed that many of them hyperactivate the kinase and can predict sensitivity to rapamycin; he also contributed to the discovery of GATOR1
- Ann-Charlotte Granholm 1 study Neuroscientist of aging who has studied Down syndrome and the Alzheimer's disease that often comes with it since the 1990s, now a professor at the University of Colorado Anschutz Medical Campus
- Nathanael S. Gray 4 studies Medicinal chemist whose lab designed Torin1, an ATP-competitive mTOR inhibitor that blocks functions of mTORC1 that rapamycin misses. His lab is also known for covalent kinase inhibitors and targeted protein degraders
- Douglas R. Green 1 study Cell death researcher known for work on apoptosis and the immune system, whose group also showed that the transcription factor Myc drives the metabolic switch of activated T cells.
- Rachel Green 1 study Biochemist who studies how the ribosome works and how cells detect and rescue stalled or colliding ribosomes, including links to the integrated stress response
- Savraj S. Grewal 1 study Calgary biochemist who uses fruit flies to work out how nutrients and growth signals such as TOR set the size of cells, organs and the whole animal
- Ingrid Grummt 1 study Last author of the 2004 Genes & Development study showing that mTOR activates TIF-IA to link rRNA synthesis to nutrients.
- Xin Gu 4 studies Cell biologist who discovered SAMTOR, the sensor that lets mTORC1 read the methyl donor SAM, as a PhD student at MIT, and who now leads a lab at Dana-Farber and Harvard Medical School studying ubiquitin-independent protein destruction by the midnolin-proteasome pathway
- Kun-Liang Guan 14 studies Showed how growth-factor and energy signals reach mTORC1 through TSC2 and Rheb, and, in parallel with the Sabatini lab, that the Rag GTPases carry the amino-acid signal. His lab also found that AMPK and mTORC1 control autophagy by phosphorylating the kinase ULK1 at different sites
- Paolo Guerra 1 study Systems biologist who tracked TORC1 and PKA signalling in single yeast cells and showed that their growth signals rise and fall with the cell cycle
- José G Guerrero-Morín 1 study Researcher at the Monterrey unit of Cinvestav in Mexico and first author of a 2020 mathematical model of how mTORC1 could tune the body's daily clock
- David A. Guertin 7 studies Built the mouse genetics that defined mTORC2's biological roles
- Laurent Guibaud 1 study First author of a 2026 case series on giving sirolimus (rapamycin) to pregnant women to treat large lymphatic malformations in their unborn babies
- Pawan Gulati 1 study First author of the study proposing that amino acids activate mTORC1 through a rise in intracellular calcium and calmodulin binding to hVps34, and later of work linking the obesity gene FTO to amino-acid sensing by mTORC1
- Fengjing Guo 1 study Orthopedic researcher at Tongji Hospital, Wuhan, and senior author of a 2026 review on how mTORC2 and RICTOR shape immune cells and inflammation
- Yakir Guri 2 studies Showed mTORC2 drives liver cancer by rewiring lipid and sphingolipid synthesis
- J. Silvio Gutkind 2 studies Showed that persistent mTOR activation exhausts epidermal stem cells and accelerates skin ageing, and targets PI3K–mTOR signalling in head-and-neck cancer, including to make tumours respond to immunotherapy
- Dana M. Gwinn 2 studies First author of the 2008 study showing that the energy sensor AMPK switches off mTORC1 by phosphorylating raptor
- Steven P. Gygi 6 studies Mass-spectrometry scientist whose Harvard lab builds large-scale proteomics methods, including the BioPlex human protein-interaction map, and contributed proteomics to the discoveries of the CASTOR and SAMTOR nutrient sensors
H
- Emilie Vander Haar 1 study First author of the 2007 study identifying PRAS40 as the link that carries insulin signals from Akt to mTOR
- Ernst Hafen 5 studies Developmental geneticist who used Drosophila to work out how insulin and TOR signalling control cell and body size, including the role of Rheb.
- Saeed A Hafez 1 study Researcher with the Aseer Health Cluster in Abha, Saudi Arabia, and first author of a 2026 mouse study testing the bee-venom peptide melittin against psoriasis-like skin inflammation
- Asami Hagiwara 1 study First author of a 2012 mouse study from Michael Hall's lab showing that liver mTORC2 tells the liver that the animal has eaten, by switching on sugar breakdown and fat production
- Jukka Hakkola 1 study Professor of Pharmacology at the University of Oulu who studies the pregnane X receptor (PXR), a liver sensor of drugs and foreign chemicals, and how it changes liver growth and metabolism
- Michael N. Hall 20 studies Discovered TOR in yeast in 1991 and established it as a central controller of cell growth that responds to nutrients. His lab later showed that TOR works in two distinct complexes, TORC1 and TORC2, only one of which is blocked by rapamycin
- Jessica L. Halle 1 study Muscle-biology researcher studying how cancer, chemotherapy and cachexia disrupt skeletal-muscle protein turnover and autophagy
- Jonathan J. Halloran 1 study First author of a 2012 mouse study showing that lifelong rapamycin does not cost the brain anything and even protects learning and memory with age; long-time member of Veronica Galvan's aging and Alzheimer's research group in San Antonio
- Jung Min Han 1 study Pharmacologist at Yonsei University who found that leucyl-tRNA synthetase, the enzyme that loads leucine onto its tRNA, doubles as the cell's leucine sensor for mTORC1, and who now studies how this enzyme links nutrients to growth signalling
- Jacob M Hands 1 study Researcher in integrative medicine and nutrition science, trained at George Washington University, who wrote a cautious review of whether off-label rapamycin is justified for healthy adults
- Malene Hansen 3 studies Showed in worms, alongside a 2007 report from Beth Levine's laboratory, that autophagy is required for dietary restriction to extend lifespan
- Kenta Hara 4 studies Showed in 1998 that amino acids are needed for mTOR to activate S6K1 and 4E-BP1, and as first author co-discovered raptor in 2002
- Girish Harinath 1 study Designs, analyses and writes up human studies of repurposed drugs such as rapamycin at a longevity telehealth company, turning trial and real-world prescription data into peer-reviewed evidence
- J. Wade Harper 2 studies Co-discovered the F-box motif that links substrates to SCF ubiquitin ligases, and co-leads with Steven Gygi the BioPlex protein-interaction map, which contributed to the discoveries of the CASTOR and SAMTOR nutrient sensors
- Laura S. Harrington 1 study First author of the 2004 study showing that TSC1-2 loss blunts insulin signalling through S6K1-driven feedback on IRS proteins
- Adrian L. Harris 1 study Medical oncologist who studies hypoxia, tumour blood-vessel growth and the metabolic response of breast cancer cells.
- David E. Harrison 7 studies Led the Jackson Laboratory site of the NIA Interventions Testing Program. His 2009 Nature paper showed that rapamycin extends the lifespan of genetically diverse mice even when feeding starts at 20 months of age, which the authors described as the first pharmacological extension of lifespan in both sexes of a mammal
- Jiaxiong He 1 study Contributing co-author in Songlin Li's aquaculture-nutrition team studying mTOR/SREBP1-driven lipogenesis in fish.
- Jiayun He 1 study Contributing co-author in Lei Luo's team studying redox-driven mTOR-eIF4A translational control.
- Linling He 1 study Researcher in the Fudan team studying amino-acid sensing and stress resilience in T cells
- Long He 1 study Research faculty member in John Blenis's lab at Weill Cornell who studies how mTORC1 controls cell metabolism, and first author of the lab's 2025 review of mTORC1 as a conductor of metabolism and growth
- Yi He 1 study Endocrinology researcher in Xuefeng Yu's group at Tongji Hospital in Wuhan who studies the liver- and fat-derived hormone ANGPTL8 in aging and diabetes
- Alexander M Heberle 2 studies Cell biologist and Junior Group Leader at the University of Innsbruck who studies how mTOR balances growth signalling and metabolism when cells are under stress, trained in Kathrin Thedieck's systems-biology group
- Markus H. Heim 1 study Basel hepatologist who studies how the liver responds to viral infection and how liver cancer develops, and a co-author of the study linking mTORC2 to fat synthesis in liver tumours
- Joseph Heitman 1 study Co-discovered the TOR genes in yeast in 1991 as a first author with Rao Movva and Michael Hall, the genetic identification of what became known as mTOR in mammals
- Samson Hennessy-Strahs 1 study Researcher who moved from studying heart pumps and blood vessels at Penn to transplant immunology in Houston, and first author of a study showing that the lung's cleaning macrophages need mTOR to survive
- Elizabeth P Henske 2 studies Tuberous sclerosis researcher and co-author of the 2026 TSC2 minipig study and the 2017 Cancer Cell paper on mTORC1 and nucleotide synthesis.
- Sujuti Hidayat 2 studies Member of Kazuyoshi Yonezawa's Kobe team that co-discovered raptor and worked out how mTOR senses amino acids, and first author of a study showing that a leucine derivative can block amino acid-mTOR signalling
- Ville Hietakangas 1 study Professor of gene regulation at the University of Helsinki who uses fruit flies to study how animals sense nutrients and how diet controls growth, metabolism and stem cells
- Dirk Hockemeyer 1 study Stem-cell biologist whose laboratory builds engineered human stem-cell and mouse models of disease, using genome editing and functional genomics screens.
- John B. Hogenesch 1 study Circadian-rhythm geneticist who uses genome-wide methods to map which genes the body clock controls in each tissue.
- Marina K. Holz 1 study Cell biologist who, as a postdoc with John Blenis, showed how mTOR and S6K1 trade places on eIF3 to start protein synthesis, and who now studies mTOR in breast cancer and the rare lung disease LAM at New York Medical College
- Jennifer Hong 1 study Neurosurgeon-scientist who studies peripheral nerve regeneration and epilepsy
- Sen Hong 1 study First-authored the cryo-EM structure identifying TM6SF1 as a lysosomal cholesterol-binding protein involved in regulating mTORC1 signalling
- Shohei Hori 1 study Senior author; laboratory head studying regulatory T cell differentiation and immune tolerance
- Marion Horsch 2 studies Scientist at the Institute of Experimental Genetics, Helmholtz Munich, who has worked with Johannes Beckers on gene-expression studies of mouse models for the German Mouse Clinic
- Gabriel N. Hortobagyi 2 studies Breast cancer physician-scientist and senior author of BOLERO-2, the phase 3 trial that showed adding the mTOR inhibitor everolimus improves outcomes in advanced hormone-receptor-positive breast cancer
- Maureen R. Horton 2 studies Pulmonary physician-scientist who studies immune mechanisms of lung inflammation and fibrosis
- Steve Horvath 1 study Biostatistician and geneticist who built the first pan-tissue epigenetic clock, a DNA methylation test that estimates biological age, and co-developed the network method WGCNA
- Nao Hosokawa 1 study Cell biologist who, in Noboru Mizushima's lab, showed how mTORC1 directly holds the autophagy starter complex in check and helped discover the autophagy protein Atg101
- Gökhan S. Hotamışlıgil 1 study Leads a Harvard laboratory on metabolic disease and was elected to the US National Academy of Sciences in 2026 for achievements in metabolic research
- Jessica J. Howell 1 study Metabolism biologist who, as a postdoc in Brendan Manning's lab at Harvard, worked out how the diabetes drug metformin switches off mTORC1 in the liver, and who later moved into drug and gene-therapy research in industry
- Gerta Hoxhaj 4 studies Studies how growth signalling through PI3K, AKT and mTOR rewires cell metabolism; as a Manning-lab postdoc she co-authored work on how metformin inhibits mTORC1 in the liver
- Andrew C. Hsieh 2 studies Showed, as first author in Davide Ruggero's lab, that oncogenic mTOR drives cancer metastasis by selectively translating a specific pro-invasion mRNA program
- Peggy P. Hsu 2 studies Identified, in parallel with Yonghao Yu's group, Grb10 as an mTORC1 substrate that feeds back to dampen insulin and growth-factor signalling, and now studies the earliest steps of lung cancer as a physician-scientist
- Cheng Hu 1 study Studies the genetics and causes of diabetes and obesity
- Ke Hu 1 study First author identifying SLC4A7/NBCn1 as a pH regulator required for mTORC1 activity and antibody-secreting cell differentiation
- Yufeng Hu 1 study First author of a 2026 Circulation study identifying LAPTM4A as a novel mTORC1 activator driving pathological cardiac hypertrophy
- Congxiu Huang 1 study Radiation oncology researcher in Hohhot and first author of a study linking the PIK3CA E545K mutation to faster growth and invasion of cervical cancer through AKT/mTOR signalling
- Haojie Huang 1 study Senior/corresponding author of a 2026 Nature Communications study identifying the SPOP–ZMYND8–NEK7 mechanism of mTOR-inhibitor resistance in kidney cancer
- Rick K. Huang 2 studies Cryo-electron microscopy specialist who, at the HHMI Janelia Research Campus, helped solve the 2018 and 2019 structures of the protein machines that pass amino acid signals to mTORC1
- Wei Huang 1 study Neuroscientist trained in Mauro Costa-Mattioli's memory lab at Baylor, first author of the study that showed mTORC2 is needed for long-term memory through control of the actin skeleton
- Lukas A. Huber 4 studies Cell biologist who studied the p14-MP1 scaffold on late endosomes, a complex later recognised as part of Ragulator (LAMTOR), the lysosomal platform that holds mTORC1 in place
- Gary Hudes 1 study Medical oncologist at Fox Chase Cancer Center who led the phase 3 trial showing that the mTOR inhibitor temsirolimus lengthens survival in poor-prognosis advanced kidney cancer
- Tony Hunter 1 study Cell biologist who showed that tyrosine phosphorylation is a master on/off switch for proteins, work that informed cancer drugs such as Gleevec; his lab also studied the TSC/Rheb/mTOR/S6K feedback to insulin signalling.
- James H. Hurley 7 studies Structural biologist who uses cryo-EM to show how protein machines assembled on membranes control autophagy and nutrient signalling. His lab solved structures of the Rag–Ragulator complex and of the whole mTORC1–TFEB–Rag–Ragulator assembly on the lysosome
- Stacy A. Hussong 1 study Studies how mTOR damages the brain's blood vessels, and how blocking it restores blood flow, the blood-brain barrier and memory in aging and Alzheimer's models
- Tuong Huynh 4 studies Research associate at Baylor College of Medicine in Houston and co-author on a long run of papers from Andrea Ballabio's group on TFEB, the master switch for lysosome and autophagy genes, including the work that tied TFEB to mTOR, starvation and fat metabolism
I
- Yuji Ikeno 2 studies Pathologist at the Barshop Institute for Longevity and Aging Studies in San Antonio whose examinations of tissues from aged mice help ageing studies tell whether an intervention changes disease, especially cancer, late in life
- Tsuneo Ikenoue 1 study Gastroenterologist and cancer researcher at the University of Tokyo who trained in Kun-Liang Guan's mTOR lab and now builds mouse models of liver, bile duct and pancreatic cancer driven by the PI3K-Akt-mTOR pathway
- Stefan Imseng 3 studies Structural biologist from Timm Maier's group at the Biozentrum Basel who helped solve the first detailed structures of human mTORC1 and mTORC2 and then worked on a drug to block mTORC1 specifically
- Nicholas T. Ingolia 1 study Known for ribosome profiling, a method that reads out which messenger RNAs ribosomes are translating across a whole genome; the study in the Atlas used this approach to map mTOR-controlled translation in prostate cancer.
- Ken Inoki 7 studies Showed as a postdoc in Kun-Liang Guan's lab that Akt switches off TSC2, that TSC2 is the off-switch (GAP) for the small GTPase Rheb, and that AMPK and GSK3 feed energy and Wnt signals into the same brake. His Michigan lab studies mTOR signalling in metabolism and kidney disease
- Karen E. Inouye 2 studies Metabolic physiologist who runs the Hotamışlıgil lab’s physiology facility, which specialises in glucose clamps, and co-authored two 2026 mouse studies on how feeding controls mTORC1 in liver and muscle.
- Beatriz Eda de Oliveira Isídio 1 study Researcher in Antonio Carlos de Freitas's laboratory at the Federal University of Pernambuco who studies whether human papillomavirus (HPV) is active in breast tumours
- Yoshinori Ito 2 studies Breast medical oncologist at the Cancer Institute Hospital in Tokyo and a co-investigator of BOLERO-2, the trial that brought the mTOR inhibitor everolimus into breast cancer treatment
- Gopa Iyer 1 study Medical oncologist at Memorial Sloan Kettering who heads its bladder cancer section and studies the genetics behind how bladder tumors respond to drugs
J
- Estela Jacinto 5 studies Co-discovered mammalian mTORC2 as a postdoc in Michael Hall's lab, showing that it controls the actin cytoskeleton and is insensitive to rapamycin. Her Rutgers lab, with Bing Su's group, was among those that found SIN1 holds mTORC2 together and studies how both mTOR complexes control metabolism
- Lauren N. Jackson 1 study Researcher in Robin Mockett's lab at the University of South Alabama who showed that rapamycin's effect on fruit fly lifespan swings from harmful to helpful depending on the food
- Matthew R. Janes 2 studies Showed, as first author in David Fruman's lab, that a dual TORC1/2 kinase inhibitor kills leukemia cells with much weaker effects on normal lymphocytes than rapamycin
- Rachel M. Jansen 2 studies First author of the cryo-EM structure showing how the arginine sensor CASTOR1 binds the GATOR2 cage when arginine is low and is released when arginine returns
- Martin A. Javors 2 studies Pharmacologist and professor at UT Health San Antonio who directs an analytical laboratory for biochemical and drug measurements, and a co-author of rapamycin studies in mice and in older people
- Harold Jefferies 1 study Biochemist who worked on S6 kinase and 5'TOP mRNA translation in George Thomas's lab and has studied the molecular machinery of autophagy in Sharon Tooze's lab since 2003.
- Paul Jenoe 1 study Protein chemist who ran mass spectrometry and protein sequencing at the Biozentrum Basel for decades and contributed protein analysis to many mTOR studies from Michael Hall's lab
- Jenna L. Jewell 1 study Studies how cells sense nutrients such as amino acids to control growth and metabolism through mTORC1
- Yi Ji 1 study Paediatric surgeon whose team studies sirolimus treatment of kaposiform hemangioendothelioma in children
- Jian Jiang 1 study Co-developed FPTT, fluorescent 'ticker tapes' that record several signalling pathways in living cells over days, including an mTOR recorder that tracked mTOR activity oscillating through the cell cycle
- Jiaqiang Jiang 1 study Member of the Nanfang Hospital gastric-cancer surgery team that traced how a tumor-enriched gut bacterium rewires CD8+ T cells through an mTOR-linked checkpoint to blunt anti-PD-1 therapy.
- Xuejun Jiang 1 study Cell biologist who studies autophagy and programmed cell death, including the ULK1-ATG13-FIP200 complex that links mTOR signalling to autophagy.
- Ning Jiao 1 study Animal nutrition scientist at Shandong Agricultural University who studies how feed contaminants such as mould toxins and bisphenol A harm pigs, and how nutrients like glutamine protect the gut
- Wafiya Jibrin 1 study Researcher at the University of Dundee School of Medicine who led a 2026 cell-culture test of whether rapamycin can shield sperm-precursor cells from the cancer drug cisplatin
- Lingyan Jin 1 study Cardiology researcher in Qiangsun Zheng's group in Xi'an who studies how metabolism and aging make the heart's upper chambers prone to atrial fibrillation
- Peng Jin 1 study Pharmaceutical scientist in Lei Luo's group at Southwest University in Chongqing who studies the drug pump P-glycoprotein, and first author of the study showing that oxidative stress boosts P-glycoprotein production through mTOR
- Christopher Johnson 2 studies Biophysicist who built and ran the Biophysics Facility at the MRC Laboratory of Molecular Biology, measuring how proteins fold, bind and change shape for dozens of research groups
- Simon C. Johnson 1 study Biologist of aging and mitochondrial disease, first author with Peter Rabinovitch and Matt Kaeberlein of the 2013 Nature review that made the case for mTOR as a central controller of aging, now a professor at Northumbria University
- Russell G. Jones 2 studies Studies how nutrient and energy sensing by AMPK and mTOR shapes cell metabolism, especially in T cells and cancer. As a postdoc with Craig Thompson he showed that AMPK triggers a p53-dependent glucose checkpoint in the cell cycle
- Jens Otto L Jørgensen 1 study Clinical professor of endocrinology at Aarhus University who studies growth hormone, the pituitary and adrenal glands and metabolism in people, and senior author of a trial showing that high-dose resveratrol did not improve metabolism in obese men
- Jay N. Joshi 1 study Showed mTORC1 activity itself rises and falls across the cell cycle, not just in response to nutrients
- Sergiusz Jóźwiak 1 study A child neurologist known for work on tuberous sclerosis complex and a senior author of the EXIST-1 trial of everolimus.
- Dean L. Kellogg Jr. 1 study A geriatrician who co-leads clinical trials of rapamycin in older adults at the Barshop Institute, with a focus on safety and cardiovascular effects.
- William G. Kaelin Jr. 1 study Cancer researcher who worked out how cells sense oxygen through the VHL and HIF proteins, work recognised by the 2019 Nobel Prize in Physiology or Medicine.
- Jennifer Jung 1 study Biochemist from Christian Behrends' group in Frankfurt who showed that the lysosomal amino acid transporter SLC38A9 helps switch on mTORC1, and who studied regulators of autophagy
- Yong-Keun Jung 1 study Studies programmed cell death and autophagy and their roles in ageing and disease, including mice with extra copies of the autophagy gene Atg5 that live longer.
K
- Matt Kaeberlein 8 studies Extended TOR/aging research from yeast to mice to pet dogs
- Ran Kafri 1 study Studies how mTORC1 sets and enforces a target size for cells
- Barry D. Kahan 1 study Transplant surgeon-scientist who was the named author of the large US trial that made sirolimus (rapamycin) an approved immunosuppressant for kidney transplant patients
- Nada Y. Kalaany 1 study Studies how a tumour's metabolism depends on the metabolic state of the whole body, and hunts for nutrient dependencies that can be turned into treatments
- Krystle C. Kalafut 2 studies Hepatic mTORC1 and nutrient signalling
- Adem Kalender 1 study Cell biologist who, in George Thomas's group at the University of Cincinnati, showed that metformin can switch off mTORC1 without AMPK by acting through the Rag GTPases
- Hanna Kalenta 2 studies Co-author of two 2026 studies on constitutive mTORC1 activation in skeletal muscle from the Rasmussen laboratory.
- Yoshiaki Kamada 1 study Showed as first author that TOR keeps autophagy switched off in yeast by controlling the Atg1 (Apg1) kinase complex, and has studied TOR's control of autophagy ever since
- Seong A. Kang 7 studies Contributed to the Sabatini-lab studies that identified PRAS40 and DEPTOR, two of the cell's own mTOR inhibitors, and to the first characterisation of the mTOR inhibitor Torin1
- Pankaj Kapahi 4 studies Showed that reducing TOR signalling extends fruit-fly lifespan, and that the translation repressor 4E-BP is needed for dietary restriction to extend it
- Michael Karin 3 studies Cell biologist best known for discovering AP-1 and JNK signaling and the IKK-NF-kB inflammation pathway, whose lab also co-led the study of Sestrin as a feedback inhibitor of TOR.
- Manikandan Karuppasamy 1 study Structural biologist who used cryo-electron microscopy at EMBL Grenoble to solve the first structure of yeast TORC2, explaining why it resists rapamycin
- Loren Kell 1 study First author identifying a direct genoprotective effect of rapamycin against DNA damage in ageing human immune cells
- George Kelly 1 study Cell biologist from Viktor Korolchuk's group at Newcastle University who showed that the routine clearing of damaged mitochondria fails as human cells become senescent
- Brian K. Kennedy 4 studies Showed with Matt Kaeberlein that reducing TOR or Sch9 signalling extends yeast lifespan in the same way as dietary restriction, and has since championed mTOR as a target for slowing human ageing
- Cynthia Kenyon 2 studies Showed in 1993 that a single-gene change doubles the lifespan of the worm C. elegans, which opened the study of nutrient-sensing pathways as ageing pathways
- Rohini V. Khapre 1 study Circadian biologist who did her PhD in Roman Kondratov's lab at Cleveland State University, where she showed that the clock protein BMAL1 acts as a brake on mTORC1 and that feeding times set a daily rhythm in mTORC1 activity
- Yoko Kidani 1 study Researcher who, in Steven Bensinger's lab at UCLA, showed that activated killer T cells need SREBP-driven fat and cholesterol synthesis to expand
- Do Jin Kim 3 studies Structural biologist, now at Denali Therapeutics, who worked in James Hurley's lab at UC Berkeley on the protein machines of autophagy and on the Rag-Ragulator complex that brings mTORC1 to the lysosome
- Do-Hyung Kim 5 studies Co-discovered raptor, the defining partner of mTOR in mTORC1, and then mLST8 (GbetaL) as a Sabatini-lab postdoc. His Minnesota lab identified PRAS40 as an insulin-regulated link to mTORC1 and studies how mTORC1 controls autophagy
- Eunjoon Kim 1 study Neuroscientist who directs the IBS Center for Synaptic Brain Dysfunctions and studies synaptic scaffold proteins linked to autism; he contributed to work linking neuronal ERBB4 and mTOR signalling to Alzheimer's pathology
- Eunjung Kim 1 study Showed as first author, in Kun-Liang Guan's lab, that the Rag GTPases relay amino-acid availability to TORC1, in parallel with the Sabatini lab's discovery
- Hyeon Soo Kim 1 study Muscle biologist working on muscle-secreted factors and treatments for sarcopenia and muscle wasting, and senior author of a study on a leucine-like drug that activates mTORC1 through Sestrin2
- Choah Kim 3 studies Researcher in David Sabatini's lab at the Whitehead Institute who contributed to three studies on how amino acids at the lysosome are sensed by mTORC1
- Joungmok Kim 3 studies Showed as a Guan-lab postdoc that AMPK and mTORC1 control autophagy by phosphorylating ULK1 at different sites, with mTORC1's mark on Ser757 blocking activation by AMPK
- Seongbin Kim 1 study Contributed to a 2026 study showing that abnormal ERBB4 in excitatory neurons drives Alzheimer's pathology through mTOR signalling
- Sunghoon Kim 1 study Senior author of the 2012 study proposing leucyl-tRNA synthetase as an intracellular leucine sensor for mTORC1, part of his broader work on the signalling roles of tRNA synthetases
- Young Chul Kim 1 study Cell biologist who studied mTOR and autophagy in Kun-Liang Guan's lab at UC San Diego and later moved to kidney research in Volker Vallon's group
- Young-Mi Kim 1 study mTOR researcher in Do-Hyung Kim's University of Minnesota lab who found SH3BP4 as a brake on the amino acid sensing Rag GTPases and showed that mTORC1 phosphorylates UVRAG to slow autophagy
- Tomohide Kinoshita 1 study First author identifying how TCR-driven mTORC1 signaling epigenetically locks in Foxp3 expression in regulatory T cells
- James L. Kirkland 2 studies Founder of the field of senolytics, drugs that clear senescent cells, and a leader of clinical trials of ageing-targeted therapies
- Lloyd B. Klickstein 2 studies A physician-scientist who led the clinical studies at Novartis showing that low-dose mTOR inhibitors can boost immune function and cut infections in older adults.
- Helene Knævelsrud 1 study Autophagy researcher who studies how cells recycle their own material and how this process is regulated in development and disease, including cancer.
- Zachary A. Knight 1 study Neuroscientist whose lab studies the brain mechanisms behind appetite, thirst and body-temperature preference; he is a co-author of the 2009 study that introduced the TORKinibs PP242 and PP30.
- Kevin E. Knockenhauer 2 studies Structural biologist trained in Thomas Schwartz's MIT lab who helped solve the amino acid sensor structures of Sestrin2 and CASTOR1, and who later moved to drug discovery at Accent Therapeutics
- Bailey A. Knopf 2 studies Graduate student in Dudley Lamming's lab at the University of Wisconsin-Madison and first author of a 2026 review that sets out the hallmarks of protein and amino acid restriction in aging
- Roman V. Kondratov 2 studies Showed the circadian clock protein BMAL1 gates TOR/mTOR signaling to control aging, and that calorie restriction's lifespan benefits require a working circadian clock
- John J. Kopchick 2 studies Discovered the growth hormone receptor antagonist that became the acromegaly drug pegvisomant (Somavert), and studies how blocking growth hormone signalling extends lifespan in mice
- Viktor I. Korolchuk 5 studies Showed that where lysosomes sit inside the cell tunes mTORC1 activity to nutrient supply. His Newcastle lab found that senescent cells can no longer switch mTORC1 off when nutrients or growth factors are withdrawn, and studies how autophagy and mitophagy decline with age
- Sara C. Kozma 12 studies Studies the S6K/mTOR pathway and how it controls cell growth, ribosome production, diabetes and cancer, including mTOR signalling in liver cancer.
- Ellen Kraig 1 study Immunologist at UT Health San Antonio who studies how aging changes immune regulation and who led the first small safety trial of rapamycin in healthy older people at the Barshop Institute
- William E. Kraus 1 study Preventive cardiologist and exercise physiologist at Duke University who leads long-running trials on how exercise and calorie restriction change human health, and senior author of the CALERIE two-year safety report
- Jonas Boritz Kristiansen 1 study Exercise biologist at Aarhus University, working with Kristian Vissing, who studies how aging changes muscle's response to mechanical load and to food
- Krešimir Krnjević 1 study Neurophysiologist who helped identify glutamate and GABA as the brain's main excitatory and inhibitory transmitters and described slow modulatory actions of acetylcholine in the cortex.
- Guido Kroemer 1 study Cell biologist known for work on programmed cell death, mitochondria and autophagy, and for linking autophagy to ageing and cancer immunity.
- Darcy A. Krueger 1 study Child neurologist who led the first trial of an mTOR inhibitor for brain tumours in tuberous sclerosis complex
- Nicholas T. Ktistakis 1 study Uses live imaging to follow the first minutes of autophagy and of mTORC1 activation
- Hiroyuki Kubota 2 studies Systems biologist who showed that the insulin pathway carries different messages in the timing of its signal, and that S6K, the mTORC1 target, reads only the fast part
- W. Michael Kuehl 1 study Physician-scientist who spent decades working out the genetic and molecular biology of multiple myeloma and its precursor condition MGUS.
- Outi Kummu 1 study Studies how chemicals activate the nuclear receptor PXR and disturb metabolism; co-author of the study linking PXR-driven liver growth to the AKT-mTOR pathway.
- Caroline Kumsta 1 study Senior author of a healthy-aging cohort study measuring autophagy flux directly across human cell types, showing it is sex- and cell type-specific and linked to physical function in older adults
- Mondira Kundu 3 studies Physician-scientist who works out what the autophagy-initiating kinases ULK1 and ULK2 actually do when a cell runs short of fuel
- Shinya Kuroda 2 studies Leads a systems biology lab that studies how cells decode the timing of hormone signals, with insulin and mTORC1-S6K as the main test case
- Takeshi Kusuda 1 study Rheumatologist and researcher at the University of Tokyo who studies how B cells go wrong in lupus, and first author of the 2026 study tying the arginine sensor CASTOR1 to mTORC1 in antibody-making cells
- David J. Kwiatkowski 7 studies Geneticist and physician who studies tuberous sclerosis complex (TSC) and the TSC1/TSC2 genes that restrain mTORC1.
L
- Remi-Martin Laberge 1 study Biologist of cell senescence, trained in Judith Campisi's lab, who showed how mTOR drives the inflammatory signals of senescent cells and then moved to drug development against senescence at UNITY Biotechnology
- Meiling Lai 1 study First author of a 2026 study of immune aging across the canine lifespan and short-term responses to rapamycin.
- Zhao Lai 2 studies Co-author of two 2026 studies on constitutive mTORC1 activation in skeletal muscle from the Rasmussen laboratory.
- Marikki Laiho 1 study Studies DNA damage, the nucleolar stress response and how RNA polymerase I (which makes ribosomal RNA) can be targeted in cancer.
- Pranav V. Lalgudi 2 studies Co-author of the cryo-EM structures of GATOR2, the nutrient-sensing hub of mTORC1, in 2022 and of GATOR2 bound to Sestrin2 and CASTOR1 in 2025
- Richard F. Lamb 1 study Studied how amino acids and growth signals reach mTOR, including the IRS feedback loop and nutrient signalling through MAP4K3
- Dudley W. Lamming 9 studies Showed as a postdoc that rapamycin's harm to glucose metabolism comes largely from its effect on mTORC2, while the lifespan benefit tracks mTORC1. His Wisconsin lab studies intermittent rapamycin dosing and how restricting dietary protein or single amino acids affects metabolism and ageing
- Agathe Landoas 1 study Hospital pharmacist at Grenoble Alpes University Hospital who studies how everolimus is used after lung transplantation and whether it protects the new lungs from long-term rejection
- Conor M. Lane 1 study Cardiologist at Mayo Clinic in Rochester, working in interventional cardiology, and first author of a trial of low-dose rapamycin in frail older adults with heart failure with preserved ejection fraction
- Antonio Lanzavecchia 1 study Human immunologist known for work on antigen presentation, memory T and B cells and methods for isolating human monoclonal antibodies; senior author of the study showing that L-arginine changes T-cell metabolism and survival independently of mTOR.
- Mathieu Laplante 3 studies Co-wrote with David Sabatini one of the field's most cited reviews of mTOR in growth and disease, and his Laval lab studies how mTORC1 and DEPTOR control fat tissue and metabolism
- Samuel C. Lapp 2 studies First author of the muscle study showing that feeding-induced mTORC1 activation through AKT–TSC2 drives postprandial protein synthesis but is not needed to build or keep muscle mass.
- Nouf N. Laqtom 3 studies Cell biologist who helped develop methods to purify intact lysosomes and used them to find what the Batten disease gene CLN3 does, and who now runs a lab at KAUST on lysosome and endoplasmic reticulum defects in rare brain and metabolic diseases
- Ola Larsson 1 study Studies how mRNA translation is altered in cancer and develops methods to measure genome-wide translation; helped show that metformin changes which mRNAs cancer cells translate, through the mTORC1/4E-BP pathway.
- Piia Lassila 1 study Researcher in Jukka Hakkola's pharmacology group at the University of Oulu who led a clinical and mouse study showing that activating the drug sensor PXR makes the liver grow
- Robert R. Latek 3 studies Bioinformatics scientist at the Whitehead Institute who worked on the Sabatini-lab papers that described raptor, mLST8 (GbetaL) and rictor (raptor and rictor were reported in parallel by other labs), the core partners of mTOR in its two complexes
- Rosalie E. Lawrence 2 studies Working in Roberto Zoncu's lab, uncovered the nutrient-driven affinity switch and the FLCN checkpoint that gate mTORC1 activation at the lysosome
- Fabienne Lebrun 2 studies Medical oncologist at the Institut Jules Bordet in Brussels and a co-author of the BOLERO-2 trial reports that brought the mTOR inhibitor everolimus into breast cancer care
- David Lebwohl 5 studies Medical oncologist and drug developer who led the clinical development of everolimus (Afinitor) at Novartis through approvals in several cancers and tuberous sclerosis, and later served as Chief Medical Officer of the gene-editing company Intellia Therapeutics
- Deborah J W Lee 1 study First author of the first systematic review of rapamycin and related drugs given to people for ageing, from the Healthy Longevity Translational Research Program at the National University of Singapore
- Jun Hee Lee 1 study Physiologist at the University of Michigan who first showed in flies that Sestrin is a feedback brake on TOR that protects against age-related decline, and has since studied Sestrins as stress-induced regulators of mTORC1
- Se Young Lee 1 study Neuroscientist in Won-Suk Chung's group at KAIST and the Institute for Basic Science who studies how neurons, astrocytes and immune cells interact in Alzheimer's disease, and first author of the 2026 Nature study on ERBB4 in excitatory neurons
- Wei Shern Lee 1 study First author of the 2021 report that brain mosaic RHEB variants cause a continuum of cortical dysplasia.
- Hsiang-Ting Lei 1 study Structural biologist from Tamir Gonen's lab who solved crystal structures of the lysosomal arginine sensor SLC38A9, showing how it holds arginine and how its own tail plugs the binding pocket
- Matthew Lelegren 1 study First author of a 2016 study of how rapamycin changes the protein-quality-control machinery in marmoset liver, muscle and fat, carried out in Adam Salmon's group in San Antonio
- Michael J. Lenardo 1 study Immunologist known for work on how immune cells die and are controlled; his lab also showed that mTOR reactivation ends autophagy and rebuilds lysosomes.
- Richard J Leventer 1 study Last author of the 2021 report on brain mosaic RHEB variants in cortical dysplasia.
- Beth Levine 1 study Discovered beclin 1, the first mammalian autophagy gene, and showed that autophagy matters for lifespan, tumor suppression and defense against viruses.
- Gang Li 1 study Researcher at the College of Life Sciences, Yantai University, and senior author of a mouse study of the plant compound pungenin and hair regrowth
- Hongliang Li 1 study Vice President of Gannan Medical University and Executive Director of its State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases; researcher of cardiovascular and metabolic diseases
- Mei Li 1 study Scientist at the Pediatrics Research Institute of Children's Hospital of Soochow University studying brain injury, who contributed to a study of how PIP4K2A protects the brain after stroke
- Meijie Li 1 study Dartmouth researcher, working with the Luikart and Hong labs, studying how PTEN controls the neuronal microtubule cytoskeleton through mTORC2 rather than mTORC1
- Ming O. Li 1 study An immunologist who studies how tumors trigger immune responses and who found that SZT2 organizes the GATOR complexes controlling mTORC1.
- Nanxin Li 1 study Neuroscientist in Ronald Duman's Yale psychiatry lab who showed in rats that ketamine's fast antidepressant effect depends on mTOR switching on new synapse growth in the prefrontal cortex
- Rui Li 1 study Toxicologist at Central China Normal University in Wuhan who leads mouse studies of how early-life exposure to microplastics, nanoplastics and plastic additives harms the developing brain
- Songlin Li 1 study Fish nutrition scientist at Shanghai Ocean University who leads research on how largemouth bass and other farmed fish use carbohydrate and other nutrients in their feed
- Thomas L. Li 1 study Co-first author of a 2026 Nature study showing mTORC1 hyperactivity drives reactive astrocytes as a primary, seizure-independent consequence of TSC2 loss, implicating glial dysfunction as a driver of tuberous sclerosis pathology
- Xian Chang Li 1 study Transplant immunologist who studies how the immune system rejects or tolerates transplants, and how drugs such as mTOR inhibitors act on immune cells.
- Xiaochun Li 1 study Solves cryo-EM structures of cholesterol-sensing membrane proteins, including the new mTORC1 regulator TM6SF1
- Jiqin Lian 1 study Biochemist studying deubiquitinase signalling in autophagy and metabolic disease
- Xiaoting Liang 1 study Toxicology and environmental health researcher who found that the long non-coding RNA LINP1 protects skin cells from radiation-induced senescence by binding mTOR
- Chun-Yan Lim 2 studies Cell biologist who trained in Roberto Zoncu's lab at UC Berkeley on how cholesterol controls mTORC1, and now publishes as corresponding author from Guangzhou National Laboratory on lysosome signalling in immunity and nutrient sensing
- Ai-Ling Lin 1 study Neuroimaging scientist who studies brain blood flow and metabolism in ageing and Alzheimer's risk, including the effect of rapamycin in people who carry APOE4.
- Shuo Lin 1 study Co-author of the 2008 mouse study showing that muscle needs raptor, the mTORC1 component, to stay healthy
- Robert A Lindquist 2 studies Researcher in David Sabatini's group at the Whitehead Institute who ran large image-based RNAi screens for regulators of TORC1 signaling and helped build the CellProfiler image-analysis software
- Jonathan O. Lipton 2 studies First author of the two studies that tie mTOR signalling to the circadian clock protein BMAL1: S6K1 phosphorylates BMAL1 to drive translation, and constant mTOR activity in tuberous sclerosis disturbs the clock.
- Edward O. List 2 studies Carries out mouse studies, in John Kopchick's group, on how disrupting growth hormone receptor signaling extends mammalian lifespan
- Andrew C. Liu 1 study Circadian biologist who studies how the body clock works at the molecular level and how it connects with metabolism and signalling pathways such as mTOR.
- Grace Y. Liu 2 studies Wrote with David Sabatini a major 2020 review of mTOR in nutrition, growth and ageing, and in the Sabatini lab studied how mTORC1 senses nutrients such as serine
- Qianqian Liu 1 study Biostatistician on one of the first randomised pilot trials of rapamycin's safety in older adults
- Qingsong Liu 1 study Medicinal chemist in Nathanael Gray's lab who helped discover Torin1, an ATP-competitive mTOR inhibitor, and later built an independent kinase-inhibitor drug-discovery program in China
- Yi Liu 1 study Drug-discovery scientist who builds selective kinase inhibitors, including the active-site mTOR inhibitor INK128
- Yu Liu 1 study Cancer biologist working on how tumour-suppressor loss and epigenetic state decide whether a cell stays differentiated
- Robbie Loewith 5 studies Showed, as first author in Michael Hall's lab, that yeast TOR exists as two distinct complexes, the basis of the TORC1/TORC2 framework
- Antje S. Löffler 1 study Cell biologist who worked in Björn Stork's group on how the autophagy kinase ULK1 talks back to the energy sensor AMPK
- Xiaomeng Long 2 studies Discovered that Rheb binds directly to the mTOR kinase domain and switches it on
- Valter D. Longo 1 study Studies how nutrient-sensing pathways (including TOR and GH/IGF-1) and diet shape ageing and resistance to stress and disease, from yeast to mice and people.
- Federica Lopes 1 study Reproductive biologist and Lecturer at the University of Dundee who studies how chemotherapy damages the immature testis and ovary, with the aim of protecting the future fertility of children treated for cancer
- Iúri Drumond Louro 1 study Professor of human and molecular genetics
- Penny Lovat 2 studies Professor of Cellular Dermatology and Oncology at Newcastle University who studies autophagy in melanoma, and whose work on the autophagy protein AMBRA1 and the skin protein loricrin underlies a test, developed with AMLo Biosciences, to identify early melanomas at low risk of spreading
- Lingjun Lu 1 study Built a computational model treating mTORC1 as a rhythm set by meal timing, not a fixed level
- Nianyin Lv 1 study Researcher at Nanjing University of Chinese Medicine who led a mouse study showing that the age-related loss of Lamtor5, a part of the lysosomal platform that helps switch on mTORC1, drives immune ageing through inflammation
- Shiqi Lv 1 study Kidney researcher at Zhongshan Hospital, Fudan University, and first author of a 2026 study tracing a chain of enzymes that switches on mTOR and drives scarring in damaged kidneys
- Guozhong Lyu 1 study Burn and wound-repair specialist in Wuxi whose group studies natural compounds, biomaterials and devices that improve healing and reduce scarring
- Yu-Xuan Lyu 1 study Corresponding/senior author of the same 2026 canine immune-aging and geroprotective-intervention study.
M
- Bodun Ma 1 study Neurology researcher in Suzhou and first author of a 2026 study on how the enzyme PIP4K2A protects the brain after stroke by restoring autophagy through AKT/mTOR
- Xiaoju Max Ma 1 study Cell biologist who trained with John Blenis on how mTOR and S6K1 control protein synthesis, wrote a widely used review of mTOR-driven translation, and later worked in cancer research at Genentech
- Maria Elena Maccari 1 study Senior author studying primary immunodeficiencies and their treatment
- Frank Madeo 2 studies Established spermidine as a dietary compound that extends lifespan in yeast, worms, flies and mice, and showed that the effect depends on autophagy
- Ahmed H. Madkour 1 study Pharmacologist at Mansoura University who tests approved drugs as protection against seizures and kidney injury in rats
- Christoph Magnes 2 studies Analytical chemist at Joanneum Research whose group contributed the mass-spectrometry measurements of polyamines in the Graz spermidine studies
- Andrea B. Maier 1 study Geriatrician-researcher who studies biological ageing and healthy longevity, including a systematic review of what rapamycin and its derivatives do in humans.
- Timm Maier 4 studies Solved some of the first cryo-EM structures of human mTORC1 (with Nenad Ban's group) and mTORC2, including a high-resolution map of mTORC2
- William B. Mair 1 study Studies how nutrient and energy sensors, and dietary restriction, control the rate of ageing, using models from yeast to mammals
- Pradip K. Majumder 1 study Cancer biologist who, in William Sellers's lab at Dana-Farber, showed that mTOR inhibitors reverse AKT-driven early prostate cancer in mice
- Smita Majumder 1 study First author of a mouse study in Salvatore Oddo's group showing that rapamycin started early in life, but not in middle age, protected against age-related memory decline
- Maria Manifava 1 study Cell biologist in Nicholas Ktistakis's group at the Babraham Institute whose live-cell imaging work spans more than two decades of research on lipid signalling, autophagosome formation and mTORC1
- Joan B. Mannick 3 studies Ran early clinical trials of low-dose mTOR inhibitors in older adults, which improved their response to flu vaccination and, in a phase 2a trial, their rate of self-reported infections; a larger phase 3 trial of RTB101 (2021) did not confirm a reduction in respiratory illness. She led this work first at Novartis and then at resTORbio
- Brendan D. Manning 17 studies Was among the groups that in 2002 identified TSC2 as a direct target of Akt (MAN2002), linking insulin and PI3K signalling to mTORC1, and later found TBC1D7 as the third subunit of the TSC complex. His lab has shown how mTORC1 turns growth signals into the synthesis of lipids and nucleotides
- Antoine Marçais 1 study Studies how mTOR and cell metabolism control natural killer (NK) cells; first author of the mouse study showing that NK cells need mTOR to respond to IL-15 during their development and activation.
- Erik D. Marchant 2 studies Graduate student in Blake Rasmussen's lab in San Antonio who studies what overactive mTORC1 in skeletal muscle does to metabolism, inflammation and exercise adaptation in aging and overnutrition
- Luca Marchetti 1 study Computational biologist building quantitative systems-pharmacology and disease models; senior author on a 2026 survival analysis of the RAP-ALS rapamycin trial
- Andrew L. Markhard 2 studies Contributed, as a Sabatini-lab researcher, to the discovery that Ragulator docks mTORC1 on the lysosome, and now studies metabolite signals that tell the body it has eaten
- Dale D. O. Martin 1 study Studies protein mislocalization and disturbed protein recycling (proteostasis) in Huntington disease and ALS.
- José A. Martina 1 study Cell biologist in Rosa Puertollano's group at the NHLBI who works on how mTORC1 and the Rag GTPases control the lysosomal transcription factors TFEB and TFE3.
- Diogo Martins-Branco 1 study Portuguese medical oncologist focused on breast cancer who moved from clinical research at the Institut Jules Bordet to the scientific division of the European Society for Medical Oncology
- Julie A. Mattison 2 studies Primate aging researcher at the US National Institute on Aging who led the NIA study of calorie restriction in rhesus monkeys and its comparison with the Wisconsin study
- Jacquelyn May 2 studies Co-author of two 2026 studies on constitutive mTORC1 activation in skeletal muscle from the Rasmussen laboratory.
- Christine Mayer 1 study First author of the 2004 Genes & Development study showing that mTOR activates TIF-IA to link rRNA synthesis to nutrients.
- Francis X. McCormack 2 studies Pulmonologist who led the MILES trial, which showed that sirolimus (rapamycin) halts the decline in lung function in lymphangioleiomyomatosis, a rare mTOR-driven lung disease.
- Maggie McNeill 1 study Paediatric haematology researcher at SickKids in Toronto and first author of a 2026 cohort study of sirolimus for Evans syndrome and other autoimmune blood-count disorders in children
- Diego L. Medina 1 study Cell biologist at the Telethon Institute of Genetics and Medicine in Naples who showed how TFEB, the master switch for lysosome genes, is controlled by calcium released from lysosomes, and who works on lysosomal storage diseases
- Lynsey Meikle 1 study Researcher in David Kwiatkowski's tuberous sclerosis lab at Brigham and Women's Hospital who built a mouse model of TSC in the brain and showed that mTOR blockers rescue it
- Alicia Meléndez 1 study Developmental geneticist at Queens College, CUNY, who showed as a postdoc in Beth Levine's lab that autophagy genes are needed for the long life of insulin-signalling mutant worms. Her lab studies autophagy in C. elegans development, from germline stem cells to meiosis
- Simon Melov 1 study Geroscientist who studies how cells and tissues change with age or drug treatment, including the finding that late-life rapamycin improves heart function in old mice.
- Delong Meng 1 study Cancer researcher at UCSF who led the preclinical test of RMC-6272, a drug that blocks mTORC1 much more strongly than mTORC2, in drug-resistant breast cancer
- Sue Menon 2 studies Showed insulin controls mTORC1 by moving the TSC complex on and off the lysosome
- Fiona Menzies 2 studies Cell biologist who worked for many years in David Rubinsztein's Cambridge lab on autophagy and the clearance of disease proteins in neurodegeneration
- Justin G. Meyerowitz 1 study Industry scientist on the team that developed RMC-5552, a bi-steric inhibitor selective for mTORC1
- Matthew Meyerson 1 study Cancer geneticist whose group has helped identify key genes mutated in lung cancer, and who contributed the cancer-genome analysis to the discovery that GATOR1 is a tumour suppressor acting on mTORC1
- Oded Meyuhas 1 study Studies how mRNAs with a 5'TOP motif, which encode ribosomal proteins, are controlled, and what phosphorylation of ribosomal protein S6 does in the cell; his lab built the knock-in mouse in which rpS6 cannot be phosphorylated.
- Chenjiao Miao 1 study Researcher in Zheng Cao's group at Northeast Agricultural University who studies how environmental and food toxins damage organs in mice, and first author of the 2026 study tying a screen chemical to kidney disease through mTOR
- Maria M. Mihaylova 2 studies Studies how intestinal stem cells change with age and how diet shapes their metabolism
- Ryan D. Michalek 1 study T-cell metabolism researcher who, as a postdoc with Jeffrey Rathmell, showed that effector CD4 T cells rely on glycolysis while regulatory T cells rely on lipid oxidation, which ties the pro-Treg effect of rapamycin to fatty acid oxidation; he later moved into metabolomics in industry
- Andreas Milias-Argeitis 1 study Follows TORC1 activity through the cell cycle in single yeast cells and builds light-controlled tools to perturb it
- Richard A. Miller 7 studies Leads the University of Michigan site of the NIA Interventions Testing Program. His papers showed that rapamycin extends mouse lifespan when started in middle age, and that the size of the benefit depends on dose and differs between males and females
- Satomi Miwa 2 studies Mitochondrial biologist who contributed to Newcastle studies on rapamycin in NF-κB-driven ageing mice and on basal mitophagy as a brake on cellular senescence.
- Noboru Mizushima 1 study Built much of the molecular map of autophagy in mammals - the ATG proteins that make an autophagosome, and the signals, including mTORC1, that decide when one is made
- Robin J. Mockett 1 study Studies ageing in the fruit fly Drosophila melanogaster, including how rapamycin and diet change lifespan.
- Mauricio Moel 1 study Analyses trial and real-world data on repurposed longevity drugs at AgelessRx and led the reporting of the PEARL rapamycin trial
- Suzette Moes 1 study Protein scientist at the Biozentrum Basel's proteomics facility who, with Paul Jenö, carried out mass spectrometry for many mTOR studies from Michael Hall's lab
- Jill de Mol 1 study Immunologist at Leiden University who studies how the aging immune system, especially aged B cells, drives atherosclerosis, and first author of a 2026 study of rapamycin as an immune rejuvenator in old mice
- Ofer Moldavski 2 studies Researcher who worked on lysosomes and lipid signalling in Roberto Zoncu's lab at UC Berkeley and was first author of a 2021 study on how the oxysterol 4beta-hydroxycholesterol switches on fat-making genes
- Jlenia Monfregola 3 studies TIGEM postdoc and co-author on the cryo-EM structure of the mTORC1–TFEB–Rag–Ragulator megacomplex and on the TBK1/ULK1 lysosomal stress route to TFEB.
- Jacques Montagne 2 studies Drosophila geneticist who, working in George Thomas's group, showed that flies lacking S6 kinase are small because their cells are small, not fewer, and helped characterise fly TOR
- Vamsi K. Mootha 1 study Studies how mitochondria are built and work and how their genes cause disease, including the MitoCarta inventory of the mitochondrial proteome and the mitochondrial calcium uniporter.
- Tatiana M. Moreno 1 study First author of a healthy-aging cohort study showing that human autophagy flux is remodeled with age in a sex- and cell type-specific way, uncoupled from autophagy-gene transcription, and responsive to a mild exercise intervention
- Kristin Moreth 2 studies Scientist at the German Mouse Clinic of Helmholtz Munich who contributed to its phenotyping of mouse models, including heart measurements
- Masahiro Morita 1 study Biochemist at UT Health San Antonio who studies how mTORC1 controls protein synthesis, mRNA decay and mitochondria, and how these links go wrong in cancer and metabolic disease
- Dirk Mossmann 1 study Biochemist in Michael Hall's Basel lab who studies how mTOR and nutrients rewire metabolism in liver cancer, and first author of the 2023 Cell study showing that arginine drives liver tumour metabolism
- Simran Motwani 1 study First author of the 2026 Nature Communications study on RICTOR, vitamin B12 diets and longevity in C. elegans.
- Robert J. Motzer 2 studies Kidney-cancer oncologist who led the RECORD-1 phase III trial showing that the mTOR inhibitor everolimus extends progression-free survival in metastatic renal cell carcinoma.
- Tarek Moustafa 1 study Researcher in hepatic metabolism and bile acid signaling
- Madhav Nilakhanth Mugale 1 study Toxicologist at CSIR-CDRI in Lucknow whose group studies how organs such as the liver and lung are injured and scarred, and how hormones and drugs change that process
- Arnab Mukhopadhyay 1 study Studies how diet and gene activity interact to set lifespan in the roundworm C. elegans; his 2026 paper links loss of the mTORC2 component RICTOR to longevity on vitamin B12-rich diets through the methionine cycle and mitophagy.
- Giancarlo Maruri Munaretto 1 study Member of the Department of Medicine at Universidade do Contestado in Santa Catarina, Brazil, and senior author of a 2026 meta-analysis of everolimus after heart transplantation
- Leon O Murphy 2 studies Cell biologist who led autophagy and mTOR drug discovery at Novartis in Cambridge, Massachusetts, and is now Chief Scientific Officer of Casma Therapeutics, a company that develops drugs acting on the autophagy-lysosome system
- Nicolas Musi 1 study Endocrinologist and aging researcher who directs the Division of Endocrinology, Diabetes and Metabolism and the Diabetes and Aging Center at Cedars-Sinai, and who studies how aging drives insulin resistance, frailty and senescence
N
- Nancy L. Nadon 5 studies Scientist and programme official at the US National Institute on Aging who oversaw research resources for aging biology and helped run the Interventions Testing Program that found rapamycin extends mouse lifespan
- Gennaro Napolitano 4 studies mTORC1-TFEB lysosomal signalling
- Alex De Nardi 1 study Mathematical modeller in Trento who applies survival and epidemic models to medical data, and first author of the 2026 re-analysis of the RAP-ALS rapamycin trial in ALS
- Masako Narita 1 study Discovered, as first author, the TASCC, a compartment in senescent cells where mTOR and autophagy work side by side to fuel the secretion of inflammatory proteins
- Masashi Narita 1 study Studies what senescent cells do to the tissue around them, and showed that mTOR position, not just mTOR activity, sets their secretory output
- Priyatosh Nath 1 study Cancer researcher in Cherie-Ann Nathan's head and neck cancer group at LSU Health Shreveport, first author of a 2026 study showing that the mTOR inhibitor everolimus can turn immune-cold tumours hot in mice
- Ashwin Nathan 2 studies Co-author on both Boston Children's Hospital studies linking mTOR signalling to the circadian clock protein BMAL1.
- Cherie-Ann O. Nathan 1 study Head and neck surgeon and cancer researcher who tests whether drugs such as the mTOR inhibitor everolimus can help patients whose tumours resist immunotherapy.
- Mona Nazemi 1 study Cell biologist in Elena Rainero's lab at the University of Sheffield who studies how the collagen-rich matrix around tumours feeds cancer cells when nutrients run short
- Francesca Nazio 1 study Cell biologist at the University of Rome Tor Vergata who, in Francesco Cecconi's lab, showed how mTOR keeps autophagy switched off by acting on AMBRA1 and the starter kinase ULK1
- Frauke Neff 2 studies First author of the study that separated what rapamycin does to lifespan from what it does to ageing itself
- Glyn Nelson 2 studies Microscopy specialist who manages Newcastle University's Bioimaging Unit and has worked for many years on the signalling networks that keep senescent cells in their arrested state
- James F. Nelson 1 study Physiologist of aging at UT Health San Antonio who studies how calorie restriction, sex hormones and drugs change mouse lifespan, and a co-investigator on the Interventions Testing Program
- Thomas P. Neufeld 1 study Uses Drosophila to study how TOR signalling controls cell growth and autophagy; his group was one of two that described the fly TOR gene in 2000
- Jianxin Ni 1 study Urologist at Xi'an People's Hospital and senior author of a 2026 multicentre study of everolimus for TSC kidney tumours, with further work on prostate cancer
- Raffaele Nicastro 1 study Cell biologist at the University of Fribourg who studies TORC1 signalling in yeast and mammals, and first author of the discovery that malonyl-CoA is a natural mTORC1 inhibitor
- Takahiro Nobukuni 3 studies Showed as first author that amino acids activate mTOR through the lipid kinase hVps34, by a route separate from insulin signalling through TSC, in parallel with a study from Jonathan Backer's laboratory
- Shinzaburo Noguchi 2 studies Breast cancer surgeon and researcher at Osaka University and a co-investigator of BOLERO-2, the trial that brought the mTOR inhibitor everolimus into breast cancer treatment
- Hiroki Nojima 1 study First author of the 2003 Kobe study showing that raptor grabs mTOR's targets through a short TOS motif, the docking step that lets mTORC1 reach its substrates
- Lyvia Neves Rebello Alves Nolasco 1 study Postdoctoral researcher in human molecular genetics
- Daniel K. Nomura 2 studies Chemical biologist and professor at UC Berkeley who uses chemoproteomics to find druggable sites on proteins, including covalent handles that turn ordinary drug molecules into protein degraders
- Abigail Nordbeck 1 study Neuroscience researcher and first author of a 2026 spatial study of the human hippocampus in Down syndrome with Alzheimer's disease, which found mTOR and insulin signalling disturbed in specific cell layers
- Julian Nüchel 3 studies Co-author on two Demetriades-lab mTORC1 papers from Cologne: the spatial split of mTORC1 signalling by amino acid source and malonyl-CoA as a direct mTORC1 inhibitor.
O
- Brendan P. O'Hara 3 studies As lab manager of Issam Ben-Sahra's lab at Northwestern, contributed to its studies of how mTORC1 and ERK control nucleotide synthesis, SAM production and bicarbonate import
- Cahir O'Kane 3 studies Fruit-fly geneticist at Cambridge who studies how the endoplasmic reticulum is built inside nerve fibres and how its failure causes hereditary spastic paraplegia, and who helped bring Drosophila models into David Rubinsztein's autophagy work
- Kathryn O'Reilly 1 study Physician-scientist who, in Neal Rosen's lab at Memorial Sloan Kettering, showed that blocking mTORC1 with rapamycin-like drugs switches on the survival kinase Akt through a feedback loop, a main reason these drugs worked less well against cancer than hoped
- Kjell Öberg 1 study A leading figure in neuroendocrine tumor research and care, and a co-author of the RADIANT-3 trial that supported everolimus for pancreatic neuroendocrine tumors.
- Alejandro Ocampo 1 study Aging researcher known for work on partial cellular reprogramming as a way to rejuvenate tissues, and senior author of a cross-species platform for screening lifespan-extending compounds
- Salvatore Oddo 2 studies Alzheimer's disease researcher who showed that amyloid-beta raises mTOR activity and that lowering mTOR with rapamycin cuts amyloid and Tau pathology in mice through autophagy
- Chang-Myung Oh 1 study Metabolism researcher at GIST in South Korea whose lab studies heart and metabolic disease in mice, including how urolithin A protects the stiff heart in HFpEF
- Shigehiro Ohdo 1 study Works on the body clock and drug timing (chronopharmacology), including how circadian rhythms control mTOR in cancer cells.
- Yoshinori Ohsumi 1 study Found the genes that make autophagy work, and with them the link from TOR to the autophagy machinery
- Hiroyuki Okazaki 1 study Pharmacologist at Daiichi University of Pharmacy in Fukuoka who studies how the body clock sets the daily rhythm of mTOR in tumours and how to time cancer drugs to match it
- Toshihiko Oki 1 study Hematology researcher who trained at the Institute of Medical Science in Tokyo and in David Scadden's lab at Massachusetts General Hospital, where he imaged mTORC1 activity in leukemia cells inside living mice
- Vincent Ollendorff 1 study Co-led the Montpellier team that built AIMTOR, a light-emitting biosensor for watching mTOR activity inside living cells, as part of his work on muscle metabolism
- Wolfgang Oppliger 1 study Long-serving Biozentrum researcher who worked for more than two decades in Basel labs, first on how proteins enter mitochondria and then on TOR signalling with Michael Hall
- Jose M. Orozco 4 studies Researcher trained in David Sabatini's laboratory at the Whitehead Institute and MIT who showed that mTORC1 senses glucose through the glycolysis metabolite DHAP
- Noriko Oshiro-Rapley 4 studies In one of several 2007 studies, identified PRAS40 as a raptor-bound mTORC1 substrate that gates access to mTORC1's other substrates
- Kathleen Ottina 2 studies Researcher in David Sabatini's lab at the Whitehead Institute and HHMI at MIT who contributed to studies of the GATOR1 amino acid off-switch, mTORC1 feedback on growth-factor signalling, and cancer drug resistance
- Guoqing Ouyang 1 study Liver surgery researcher at Guangxi Medical University and senior author of a 2026 study in which the plant compound notoginsenoside R1 eased paracetamol liver injury by boosting autophagy
P
- Michael E. Pacold 1 study Radiation oncologist and chemical biologist at NYU Langone who studies the metabolism of brain tumours, and a co-author of the Sabatini lab's structure of the leucine sensor Sestrin2
- Michele Pagano 1 study Studies ubiquitin ligases, the enzymes that tag proteins for destruction, including how the S6K1 kinase triggers degradation of the translation brake PDCD4.
- Duojia Pan 1 study Fly geneticist best known for work on the Hippo organ-size pathway. In 2002 his group reported that the Tsc1 and Tsc2 tumour suppressors act upstream of TOR to restrain S6K activity, in flies and mammalian cells
- Jiyoung Pan 1 study PhD student who co-authored the 2024 study showing that mTORC1 does different jobs at the lysosome and away from it, and first author of a 2026 review on why mTORC1 is better seen as a substrate-selective kinase than an on/off switch
- Pier Paolo Pandolfi 2 studies Showed that ERK directly phosphorylates and inactivates TSC2, wiring Ras/MAPK signalling into mTORC1 control, and that blocking mTORC1 in patients' tumours triggers a feedback rise in MAPK signalling
- Nicolas Panchaud 1 study Biochemist who, during a PhD with Claudio De Virgilio in Fribourg, showed that the yeast SEACIT complex switches off TORC1 when amino acids run out, and who later moved into clinical drug development at Novartis
- Luis F. Parada 1 study Uses genetically engineered mouse models to study nervous system tumours such as glioblastoma and neurofibromatosis-related tumours, and the brain effects of PTEN loss.
- Jack M. Parent 1 study Neurologist and stem-cell researcher who rebuilds human epilepsies in patient-derived neurons to find what goes wrong
- Hyun Woo Park 1 study Biochemist at Yonsei University who trained with Kun-Liang Guan on the Hippo-YAP/TAZ growth pathway and now studies how cancer cells change their signalling and metabolism to spread
- Ji-Man Park 1 study Autophagy researcher in Do-Hyung Kim's University of Minnesota lab who mapped how the kinase ULK1 starts autophagy, and lead author of work showing that AMPK can hold ULK1 back under energy stress
- Anita Parmigiani 1 study Molecular biologist who worked in Andrei Budanov's lab at Virginia Commonwealth University on Sestrins, stress-induced proteins that hold back mTORC1
- Ramon Parsons 1 study Cancer geneticist whose Columbia group identified the PTEN tumour suppressor gene in 1997, in parallel with another team; his lab then studied what goes wrong downstream of PTEN loss, including mTOR
- Linda Partridge 3 studies Showed that rapamycin extends fruit-fly lifespan through TORC1, via autophagy and reduced protein synthesis, and that it adds benefit even on top of dietary restriction
- Martin Pass 1 study Pharmaceutical drug-discovery leader who worked on AstraZeneca's oncology small-molecule programs, including the ATP-competitive mTOR kinase inhibitor AZD8055.
- João F. Passos 1 study Studies how senescent cells, mitochondria and telomeres contribute to ageing and age-related disease.
- Debasish Paul 1 study Postdoctoral fellow in Steven Cappell's lab at the National Cancer Institute who studies how ubiquitin ligases time the start of the cell cycle, and who found that mTOR briefly switches off the APC/C to give cells a burst of glycolysis as they start to divide
- Nikola P. Pavletich 2 studies Solved the crystal structure of the mTOR kinase, revealing the FRB domain as a gatekeeper of its active site, and later showed how RHEB switches mTORC1 on and PRAS40 blocks it
- Erika L. Pearce 1 study Immunologist who studies how metabolism controls T-cell fate. As a postdoc at Penn she showed in mice that drugs that raise fatty acid oxidation, metformin and rapamycin, increase CD8 memory T cells
- Samuel Peña-Llopis 1 study Cancer geneticist who, in James Brugarolas's lab, found that mTORC1 controls expression of lysosomal V-ATPase genes through TFEB; his group now studies BAP1-mutant uveal melanoma, kidney cancer and cholangiocarcinoma.
- Mario Pende 2 studies Studies how nutrients and growth factors set cell size and metabolism through mTOR and S6 kinase; as a student in George Thomas's lab he helped show that mice lacking S6K1 have small pancreatic beta-cells and low insulin.
- Min Peng 1 study Immunologist at Tsinghua University who, as a postdoc at Memorial Sloan Kettering, identified Sestrins and SZT2 as brakes on mTORC1 and now studies how T cells grow, specialise and remember
- Rushika M. Perera 2 studies Professor of Anatomy at UCSF whose lab studies how autophagy and the lysosome, the cell's recycling centre, help cancer cells cope with stress, and a co-author of two Science papers on how lysosomal cholesterol switches on mTORC1
- Alejandra Perez 2 studies Breast cancer oncologist in South Florida who enrolled patients in BOLERO-2, the trial that brought the mTOR inhibitor everolimus into breast cancer treatment
- Kevin Perez 1 study Aging researcher and co-founder of the Swiss company EPITERNA, working with Alejandro Ocampo's lab at the University of Lausanne on screening platforms that look for drugs extending lifespan across several species
- Viviana I. Pérez 1 study Aging biologist who studied protein homeostasis in long-lived species and how rapamycin and dietary restriction act in mice, and who now directs the National Institute on Aging's Division of Aging Biology
- Julie Perroy 1 study Neurobiologist who co-led AIMTOR, a biosensor for watching mTOR activity live in single cells and in separate parts of the cell
- Timothy R. Peterson 6 studies Discovered DEPTOR, an inhibitor that binds mTOR in both complexes and is overexpressed in some multiple myelomas. He also showed that mTORC1 controls fat synthesis by regulating where the enzyme lipin 1 sits in the cell, and through it the SREBP pathway
- Constance Petit 1 study Cell biologist who showed, in Shawn Ferguson's lab at Yale, that folliculin moves onto lysosomes when amino acids run out and is needed to switch on the Rag GTPases
- Piero Dalle Pezze 2 studies First author of two Atlas modelling studies: the dynamic insulin–mTOR network model (TSC-independent mTORC2) and the systems study of concurrent AMPK and mTOR activation by amino acids.
- Patrick C. Phillips 1 study Evolutionary geneticist who uses the nematode C. elegans to study aging, including how insulin/IGF-1 signalling, a pathway tightly connected to mTOR, shapes lifespan.
- Kiryl D. Piatkevich 1 study Protein engineer who designs fluorescent proteins and biosensors for imaging cells and brains, trained with Vladislav Verkhusha and Edward Boyden, now running a lab at Westlake University
- Martine J. Piccart 2 studies Breast cancer oncologist who co-founded the Breast International Group and has led or co-led major academic trials such as HERA, MINDACT and ALTTO.
- Denisa Pirscoveanu 1 study Neurology researcher in Craiova who works with Aurel Popa-Wagner on aging and stroke, and first author of a 2026 review on why mTOR-type lifespan gains shrink from worms to mammals
- Erica Pledger 1 study Researcher in Jamie Cate's lab at UC Berkeley who used ribosome profiling to show that exhausted human T cells shut down a key class of growth-related mRNAs even while mTOR is active
- Natalia Podlutskaya 2 studies Contributed, at the Barshop Institute in San Antonio, to mouse studies showing that rapamycin prevents Alzheimer's-like memory loss and improves cognition in normal ageing
- Katrina Podsypanina 1 study First author of the study showing that an mTOR inhibitor reduced tumour growth and S6 kinase activity in Pten+/- mice; later moved from cancer genetics to tumour immunology
- Pazit Polak 1 study Cell biologist from Michael Hall's Basel lab who showed, in mice, that switching off mTORC1 in fat tissue alone makes animals lean and protects them from diet-induced obesity
- Kristen N. Pollizzi 2 studies Immunologist trained in Jonathan Powell's lab at Johns Hopkins who used gene deletions in mice to show how the two mTOR complexes push killer T cells toward effector or memory fates
- Aurel Popa-Wagner 1 study Neuroscientist of brain aging and stroke recovery working between Craiova and Essen, senior author of a 2026 review on the limits of extending lifespan through the mTOR pathway
- Thomas Porstmann 1 study Cell biologist who, as a researcher in Almut Schulze's laboratory at the Cancer Research UK London Research Institute, showed that the growth kinase Akt drives fat synthesis through SREBP and that this route runs through mTORC1
- Christopher J. Potter 1 study As a PhD student with Tian Xu at Yale, showed in Drosophila that Akt directly phosphorylates Tsc2 and breaks up the Tsc1-Tsc2 complex, one of several 2002 papers that connected insulin-Akt signalling to TSC. He now studies insect olfaction
- Morten Poulsen 1 study Endocrinologist at Aarhus University Hospital who led one of the first careful human trials of high-dose resveratrol, which found no metabolic benefit in obese men
- Jonathan D. Powell 4 studies Showed that T cells lacking mTOR become regulatory T cells instead of effector cells, and that mTORC1 and mTORC2 each steer a different type of helper T cell
- R Wilson Powers 1 study Molecular biologist who, as a PhD student in Seattle, built high-throughput lifespan screens in yeast and showed that lowering TOR signalling extends chronological lifespan, and who later became a patent attorney
- Mirja Tamara Prentzell 2 studies First author of the study showing that G3BP proteins anchor the TSC complex to lysosomes, a physical brake on mTORC1; earlier co-author on the dynamic insulin–mTOR network model.
- Kathleen Pritchard 2 studies Breast cancer medical oncologist at Sunnybrook in Toronto, professor emerita at the University of Toronto and long-time leader of breast cancer trials, co-author of the BOLERO-2 everolimus trial
- Rosa Puertollano 2 studies Studies how lysosomes are regulated, including how mTORC1 controls the transcription factors TFEB and TFE3 that switch on autophagy and lysosome genes.
- Pere Puigserver 1 study Metabolism researcher who studies how mitochondrial energy production and nutrient metabolism are controlled, including the finding that mTOR drives mitochondrial gene activity through YY1 and PGC-1alpha.
- Cassidy P. Pumper 2 studies Member of Dudley Lamming's group at the University of Wisconsin-Madison who contributed to the intermittent rapamycin studies in mice
- Jong-Ok Pyo 1 study Autophagy researcher in Yong-Keun Jung's group in Korea, and first author of the 2013 study in which mice with an extra dose of the autophagy gene Atg5 lived longer
Q
- Zhenpeng Qiu 1 study Pharmacologist and Professor at Hubei University of Chinese Medicine who studies how natural medicines act on liver and kidney disease, including fatty liver disease and drug-induced organ damage
- Dean Quinn 2 studies Clinical trial investigator at P3 Research in Wellington, New Zealand, who was a co-author of the resTORbio trials that tested low-dose mTOR inhibitors to strengthen immunity in older adults
R
- Peter S. Rabinovitch 1 study Uses mouse models to study how improving mitochondrial function changes lifespan and healthspan, including catalase-overexpressing mice and the drug elamipretide (SS-31)
- Simon Raffel 1 study Studies metabolic vulnerabilities of leukemia stem cells; senior author on a 2026 Blood paper on IDH3, citrate and mTORC1 in AML stem cell drug resistance
- Elena Rainero 1 study Studies how cancer cells use the extracellular matrix as a nutrient and signaling source; senior author on a 2026 study linking collagen I to mTORC1 activation in cancer cells
- Chidambaram Ramanathan 1 study Circadian biologist at the University of Memphis who showed that mTOR signalling sets the speed and strength of the body's daily clocks
- Pengcheng Rao 1 study Researcher at the West China Hospital of Stomatology in Chengdu who led a genome-wide CRISPR screen showing that switching off mTOR can help cancer cells tolerate cisplatin
- Rajesh R. Rao 1 study First author of mouse studies in Protul Shrikant's group showing that mTOR activity decides between effector and memory fates in CD8 T cells by controlling T-bet and Eomesodermin
- Blake B. Rasmussen 3 studies Muscle physiologist who studies how mTORC1 and nutrient signaling control muscle growth and loss in people, including during exercise and aging.
- Birgit Rathkolb 2 studies Scientist at the German Mouse Clinic of Helmholtz Munich and the Gene Center of LMU Munich who contributes to the clinic's phenotyping of mouse models
- Jeffrey C. Rathmell 1 study Studies how nutrients and metabolic pathways control lymphocyte growth, differentiation and function; his lab helped show that effector and regulatory CD4 T cells rely on different fuel programmes, glycolysis versus lipid oxidation (in mouse cells).
- Boglarka Rauch 1 study Researcher in Péter Bai's group at the University of Debrecen who studies how ADP-ribosylating enzymes control fat cell development through AMPK and mTOR
- Brinda Ravikumar 2 studies First author of the 2004 study showing that switching off mTOR clears the toxic protein of Huntington disease by autophagy
- Eric Ravussin 1 study Human energy-metabolism researcher who studies why people differ in how they burn energy and what long-term calorie restriction does to the body, including in the CALERIE trial.
- Manuele Rebsamen 1 study Cell biologist who found that the lysosomal transporter SLC38A9 is part of the amino acid sensor for mTORC1, and who now leads a group at the University of Lausanne studying transporters in immune signalling and autoimmunity
- Yingxin Ren 1 study Gastric cancer researcher in Yanfeng Hu's surgical group at Nanfang Hospital who studies how tumour bacteria and metabolism shape resistance to immunotherapy
- Arlan Richardson 7 studies Studies how rapamycin slows ageing in mice, including the broad changes it causes in the liver, and co-authored early studies showing that rapamycin protects memory in Alzheimer's-model mice
- Beatrice Rivalta 1 study First author of a multicenter registry analysis comparing rapamycin and leniolisib in a rare immune disorder
- Stacey Robida-Stubbs 1 study Researcher in Keith Blackwell's worm lab at the Joslin Diabetes Center who showed that TOR inhibition and rapamycin extend C. elegans lifespan through the protective factors SKN-1/Nrf and DAF-16/FoxO
- Aaron M. Robitaille 1 study Mass spectrometry scientist who, as a PhD student in Michael Hall's lab, used phosphoproteomics to show that mTORC1 switches on the cell's production of pyrimidines, and who now works on proteomics applications at Thermo Fisher Scientific
- Agnes Roczniak-Ferguson 1 study Cell biologist in Shawn Ferguson's lab at Yale who showed that mTORC1 phosphorylates the transcription factor TFEB to control lysosome and autophagy genes, and who studies lysosome biology in neurodegenerative disease
- Vanessa S. Rodrik-Outmezguine 2 studies Showed that tumours reactivate AKT after mTOR kinase inhibition, and that the third-generation inhibitor RapaLink-1 overcomes mTOR resistance mutations
- Kacper B. Rogala 4 studies Solved the near-atomic cryo-EM structure that shows how mTORC1 physically docks at the lysosome by reading the Rag GTPases
- Sergei V. Romashkan 1 study Physician scientist at the National Institute on Aging who oversees clinical trials in older adults and led the safety analysis of CALERIE, the first long-term trial of calorie restriction in healthy people
- Fredrick J. Rosario 1 study Studies how mTOR signalling in the placenta controls the transport of amino acids and folate to the fetus
- Bradley Rosen 1 study Los Angeles physician, originally trained as a retina specialist, who runs a longevity-medicine practice built around rapamycin and metformin, and senior author of a cautious review of the human evidence for off-label rapamycin in healthy adults
- Neal Rosen 3 studies Showed that blocking mTORC1 releases a feedback brake on receptor tyrosine kinases and AKT, explaining how tumours escape mTOR and PI3K inhibitors and shaping how these drugs are combined in the clinic
- Jonathan E. Rosenberg 1 study A bladder and urothelial cancer oncologist whose clinical trial work includes the case of an exceptional responder to everolimus with activating MTOR mutations.
- Corinna Ross 3 studies Primate biologist at Texas Biomedical Research Institute who uses the common marmoset to test whether drugs such as rapamycin can protect health during aging
- Avik Roy 1 study Neuroscientist who studies brain inflammation in Parkinson's disease and now leads research on ME/CFS as Chief Scientific Officer of the nonprofit Simmaron Research
- Jan Rozman 2 studies Scientist who worked at the German Mouse Clinic of Helmholtz Munich on the standardised phenotyping of mouse models
- David C. Rubinsztein 2 studies Showed that rapamycin induces autophagy to clear the toxic protein of Huntington's disease, and that where lysosomes sit inside a cell helps set mTORC1 activity
- Christoph Ruckenstuhl 2 studies Yeast geneticist who works out how amino-acid restriction and vacuole acidity set lifespan
- Markus A. Rüegg 4 studies Neurobiologist at the Biozentrum of the University of Basel who studies how muscles and the nerve connections that drive them develop, age and fail, including the role of mTOR signalling in muscle.
- Davide Ruggero 4 studies Showed that oncogenic mTOR signalling reprograms which mRNAs are translated, and that tumours become addicted to this through the 4E-BP–eIF4E axis. His UCSF lab found that mTOR-driven translation of a specific set of mRNAs promotes prostate cancer invasion and metastasis
- Hope Rugo 2 studies Breast cancer oncologist and clinical trialist, long at UCSF, who helped run BOLERO-2 and studied how to manage the side effects of mTOR inhibitors such as everolimus
- Ryan C. Russell 1 study Studies how the nutrient-sensing kinases mTORC1, ULK1 and AMPK control the autophagy machinery; as a postdoc with Kun-Liang Guan he showed that ULK1 phosphorylates Beclin-1 to switch on the autophagy-specific VPS34 complex.
- Igor Ruvinsky 1 study Biochemist from Oded Meyuhas's Jerusalem lab who made the mouse in which ribosomal protein S6 cannot be phosphorylated, showing that this mark controls cell size and blood sugar rather than the translation of TOP mRNAs
S
- Bernardo L. Sabatini 1 study Neurobiologist who studies how synapses and circuits change during development and learning; his lab showed that loss of Tsc1 in mouse hippocampal neurons weakens inhibitory input and tips circuits toward hyperexcitability.
- David M. Sabatini 57 studies Identified mTOR (as RAFT1) in 1994. His lab then mapped much of the machinery around it: raptor and rictor at the core of mTORC1 and mTORC2, the Rag–Ragulator system that docks mTORC1 on the lysosome, and the sensors that detect leucine, arginine and SAM
- Abdelhafid Saci 1 study Cell biologist who, in Christopher Carpenter's lab at Beth Israel Deaconess, found that the small GTPase Rac1 binds mTOR and helps set the activity and location of both mTOR complexes
- Junichi Sadoshima 2 studies Studies how mTOR, autophagy and mitophagy protect the heart under stress and in ageing, and contributed to the finding that spermidine protects the heart
- Marcus D. Säemann 1 study Nephrologist who showed that the TSC-mTOR pathway controls the innate inflammatory response
- Mustafa Sahin 3 studies Senior author of the studies showing that mTOR signalling reaches the circadian clock through BMAL1, and a physician-scientist focused on tuberous sclerosis, the classic disease of overactive mTOR.
- Tarek Sahmoud 3 studies Physician and epidemiologist who worked as a clinical program head in Novartis oncology drug development during the everolimus trials, and later as chief medical officer at several cancer drug companies
- Umakant Sahu 2 studies Showed that the building blocks of RNA also tell mitochondria how fast to burn fuel
- Adam B. Salmon 11 studies Biologist of aging at UT Health San Antonio whose work in this Atlas spans rapamycin in mice and in common marmosets. He is a co-author on the Interventions Testing Program reports from the San Antonio site and on the marmoset rapamycin studies on blood markers, epigenetic age and the salivary gland
- Julian R. Sampson 2 studies Clinical geneticist who led the consortium that identified the TSC2 gene and led trials of mTOR inhibitors in tuberous sclerosis, including the TRON trial of everolimus for cognition.
- Yasemin Sancak 5 studies Showed as a Sabatini-lab graduate student, in parallel with Kun-Liang Guan's lab, that the Rag GTPases relay amino-acid signals to mTORC1, and that Ragulator anchors them to the lysosome where mTORC1 is switched on. She also identified PRAS40 as an insulin-regulated inhibitor of mTORC1
- Zixin Sang 1 study Chemical biologist at SUSTech in Shenzhen who used a light-activated methionine probe to identify PKM2 as a methionine sensor for mTORC1
- Moisés Santillán 1 study Builds mathematical models of biological regulation, including how the circadian clock and mTORC1 influence each other
- Dos D. Sarbassov 5 studies Discovered rictor as a Sabatini-lab postdoc, in parallel with Michael Hall's lab, defining mTOR Complex 2, and showed that this complex is the long-sought kinase that phosphorylates Akt on serine 473. He also found that prolonged rapamycin treatment can block mTORC2 assembly
- Marco Sardiello 1 study Geneticist who, in Andrea Ballabio's group, helped show that lysosomal genes share a promoter motif and are switched on together by the transcription factor TFEB; his lab now works on lysosomal storage diseases, especially the neuronal ceroid lipofuscinoses.
- Timothy J. Sargeant 1 study Studies lysosomal recycling and autophagy in ageing and Alzheimer's disease, and develops ways to measure autophagy flux in people.
- Tatsuhiro Sato 1 study First author of the study that found single amino-acid changes in mTOR, taken from cancer genome databases, that keep mTOR signalling on during nutrient starvation
- Leslie J. Saucedo 1 study Fruit-fly cell biologist and teacher who, as a postdoc in Bruce Edgar's lab, showed that the small GTPase Rheb drives cell growth in the insulin/TOR pathway
- Evelyn Sauer 2 studies Structural biologist at the Biozentrum Basel who worked on the structure of the mTOR kinase and contributed to the cryo-EM structures of human mTORC1 and mTORC2
- Charles L. Sawyers 2 studies Physician-scientist known for targeted cancer drugs (ABL inhibitors in leukaemia, antiandrogens in prostate cancer); his UCLA lab helped show that PTEN-deficient tumour cells depend more on mTOR
- Anurag Saxena 1 study Clinical research fellow at Cardiff University who coordinated TRON, a placebo-controlled trial testing whether everolimus improves memory and thinking in adults with tuberous sclerosis complex
- Robert A. Saxton 8 studies Solved, as a Sabatini-lab graduate student, the structures of the leucine sensor Sestrin2 and the arginine sensor CASTOR1, showing how each one grips its amino acid. He also co-wrote a widely cited 2017 review of mTOR signalling with David Sabatini
- David T. Scadden 1 study Stem cell and leukaemia biologist whose lab imaged mTORC1 activity in live mice and showed that well-timed mTORC1 inhibition kills more leukaemia cells
- Alain Scaiola 2 studies Structural biologist in Nenad Ban's group at ETH Zurich who solved the 3.2-angstrom cryo-EM structure of human mTORC2 and works on how ribosomes are built and how new proteins are processed
- Sonia M. Scaria 5 studies Contributed, as an MIT undergraduate in the Sabatini lab, to the discovery of CASTOR1 as the arginine sensor and SAMTOR as the SAM sensor of the mTORC1 pathway
- Sebastiano Sciarretta 1 study Cardiologist and heart researcher at Sapienza University of Rome who trained with Junichi Sadoshima on how mTOR and autophagy protect or harm the stressed heart
- Luca Scorrano 1 study Mitochondrial biologist known for showing how the shape of mitochondria and their inner folds (cristae) control energy production and cell death.
- Randy J. Seeley 1 study Studies how gut and brain signals control appetite, body weight and blood sugar, including why bariatric surgery works; his Cincinnati lab was senior on the rat study linking hypothalamic mTOR to food intake.
- Surendra Nath Sehgal 1 study Led the team at Ayerst that isolated rapamycin from an Easter Island soil bacterium and kept the program alive until the drug reached the clinic.
- Christian Sell 1 study Studies the basic biology of ageing, especially how mTOR, rapamycin, cellular metabolism and senescence are connected.
- William R. Sellers 1 study Cancer biologist and physician-scientist whose work spans cancer genomics and cancer therapeutics, including how the PI3K/AKT/mTOR pathway drives tumours and how to target it.
- Colin Selman 1 study Biogerontologist who studies how diet and nutrient-sensing pathways such as insulin/IGF-1 and mTOR set the pace of ageing
- Shomit Sengupta 3 studies Showed that mTORC1 controls whether the liver makes ketone bodies during fasting, and now leads biology for drug discovery at a metabolic-disease biotech
- Carmine Settembre 3 studies Showed, as first author in Andrea Ballabio's lab, that TFEB drives autophagy as well as lysosome production, and, in parallel with other groups, that mTORC1 phosphorylates TFEB at the lysosome to keep this program switched off when nutrients are plentiful
- David B. Shackelford 2 studies Cancer biologist at UCLA who studies lung tumours that have lost the LKB1 tumour suppressor, the upstream activator of AMPK, and who trained in Reuben Shaw's lab at the Salk Institute
- O. Jameel Shah 1 study Cell biologist in Tony Hunter's lab at the Salk Institute who showed that runaway Rheb-mTOR-S6K signalling destroys the insulin receptor's helper proteins IRS1 and IRS2, one half of the discovery of the S6K-IRS feedback loop
- Sohel Shaikh 1 study Senior author of the same 2026 systematic review of senolytic and anti-ageing drug trials in humans.
- Daryl P. Shanley 2 studies Systems biologist of ageing whose Newcastle modelling group built, with the Thedieck lab, the dynamic models of mTOR signalling in the Atlas.
- Zelton Dave Sharp 3 studies Molecular biologist at UT Health San Antonio who works on rapamycin and aging in mice, from the Interventions Testing Program lifespan studies to cancer prevention in tumour-prone mice
- Reuben J. Shaw 5 studies Showed, in parallel with two other groups, that the tumour suppressor LKB1 directly activates AMPK, and that AMPK brakes mTORC1 by phosphorylating raptor. His Salk lab also linked AMPK to autophagy through ULK1 and helped explain how metformin acts in the liver
- Kuang Shen 8 studies Solved, as a Sabatini-lab postdoc, cryo-EM structures of GATOR1 and of the FLCN–FNIP2–Rag–Ragulator complex, two switches that set mTORC1 activity. His UMass Chan lab studies the structural basis of nutrient sensing
- Sarb Shergill 1 study Senior author of the 2021 report of resTORbio's phase 2b and phase 3 trials of the mTOR inhibitor RTB101 to protect older adults from respiratory infections
- Matthew L. Sherman 1 study Oncologist and drug developer who led clinical programmes at Wyeth, including the sponsor side of the phase II temsirolimus (CCI-779) dose study in kidney cancer.
- Liyun Shi 1 study Immunologist at Zhejiang Shuren University in Hangzhou whose group showed in mice that losing the lysosomal mTOR-activating protein Lamtor5 with age pushes macrophages into senescence and spreads inflammation
- Jae Ho Shim 1 study Medicinal chemist in Hyeon Soo Kim's group at the Department of Anatomy, Korea University College of Medicine, who designs small molecules, and first author of the study of the D-leucine prodrug DLMEH that switches on mTORC1 through Sestrin2
- Hiroshi Shimada 1 study Obstetrician-scientist from Sapporo Medical University working in the Colorado placenta group of Thomas Jansson, Theresa Powell and Fredrick Rosario on how mTOR controls nutrient transport to the fetus
- Mitsugu Shimobayashi 3 studies Metabolism researcher who trained with Michael Hall in Basel on mTOR in fat tissue and now leads a group at KU Leuven studying how fat and liver control sugar and lipid storage
- Hijai R. Shin 1 study Cell biologist who discovered, in Roberto Zoncu's lab at UC Berkeley, that the lysosomal protein LYCHOS senses cholesterol for mTORC1, and who now works at the Children's Medical Center Research Institute at UT Southwestern
- Kevan M. Shokat 4 studies Co-developed the ATP-competitive 'TORKinib' mTOR inhibitors that block both mTORC1 and mTORC2, and later, with Neal Rosen's lab at Memorial Sloan Kettering, RapaLink-1, a third-generation inhibitor that overcomes mTOR resistance mutations
- Boris Shor 1 study First author of the 2010 Journal of Biological Chemistry study on mTOR, Maf1 and RNA polymerase III transcription.
- Protul A. Shrikant 1 study Tumour immunologist whose Roswell Park group showed in mouse CD8 T cells that mTOR activity, driven by IL-12, decides between effector and memory fates through T-bet and Eomesodermin
- Stefanie S. Schalm 1 study Cell biologist who, in John Blenis's lab, showed that the TOS motif lets raptor grab 4E-BP1 so mTORC1 can phosphorylate it, and who later moved into cancer drug discovery in the biotech industry
- Ingrid E. Scheffer 1 study Paediatric neurologist and epilepsy researcher who defined new epilepsy syndromes and helped identify epilepsy genes, including DEPDC5, a GATOR1 gene that connects inherited focal epilepsy to the mTOR pathway.
- Stefan M. Schieke 1 study Physician-scientist who, as a postdoc at the NHLBI, helped show that mTOR-raptor activity tracks mitochondrial oxygen consumption in human cells; his lab now studies the metabolism of lymphoid cancers.
- Alison M. Schram 1 study Medical oncologist at Memorial Sloan Kettering who runs first-in-human cancer drug trials, including the first trial of RMC-5552, an mTORC1-selective inhibitor
- Stuart L. Schreiber 2 studies Co-discovered mTOR in 1994 (his group called it FRAP) as the mammalian target of the FKBP12–rapamycin complex, and helped found chemical biology as a field
- Sabrina Schroeder 2 studies Researcher in Frank Madeo's group at Graz who has contributed to the spermidine studies from the first yeast longevity experiments to work in mice
- Almut Schulze 1 study Studies how growth signaling, including PI3K/Akt and mTORC1, drives the metabolism that cancer cells need, notably fat synthesis through SREBP.
- Erin M. Schuman 1 study Studies how neurons make and break down proteins locally in dendrites and axons; her group helped tie a rapamycin-sensitive mTOR pathway to the protein-synthesis-dependent phase of synaptic plasticity.
- Thomas U. Schwartz 2 studies MIT structural biologist who studies how molecules pass across the nuclear envelope, and whose crystallography lab helped solve the leucine and arginine sensor structures upstream of mTORC1
- Francesca Sillito 1 study Haematologist at the Royal Marsden Hospital and University College London with a special interest in CAR-T cell therapy and lymphoma, whose PhD showed that forcing mTORC1 on in CD4+ T cells makes them last longer but tire out
- Aubrey M. Sills 1 study Researcher at the Barshop Institute in San Antonio who worked with common marmosets in Adam Salmon's group and led the 2018 study of long-term rapamycin and blood health in these small primates
- Alcino J. Silva 1 study Studies the molecular and cellular basis of learning and memory, including how overactive mTOR signaling in tuberous sclerosis impairs memory and how rapamycin can reverse it in mice.
- Stephen J. Simpson 1 study Biologist who began with how locusts choose their food and is known for the Geometric Framework for nutrition, which shows that the balance of protein, carbohydrate and fat shapes health and lifespan; inaugural academic director of the Charles Perkins Centre
- David A. Sinclair 2 studies Geneticist of aging at Harvard Medical School, known for work on sirtuins, NAD+ and the idea that aging stems from a loss of epigenetic information, who appears in this Atlas as a co-author on two mouse lifespan studies
- Linda V. Sinclair 1 study T cell immunologist at the University of Dundee who works out how amino acid supply, through transporters such as SLC7A5, feeds mTORC1 and decides what activated T cells become
- Mandeep Singh 1 study Interventional cardiologist and professor of medicine at Mayo Clinic; corresponding author on a 2026 trial of low-dose rapamycin in frail older adults with heart failure with preserved ejection fraction (HFpEF)
- Sanjna Singh 1 study Autophagy researcher in Timothy Sargeant's group in Adelaide who measures autophagy directly in human blood cells and led a diet trial testing whether eating less protein switches it on in people
- David B. Solit 1 study Physician-scientist who used whole-genome sequencing of an exceptional responder to show that TSC1 mutations can predict sensitivity of bladder cancer to the mTOR inhibitor everolimus.
- Samantha M. Solon-Biet 1 study Nutrition and ageing researcher at the Charles Perkins Centre who uses the Geometric Framework to study how protein, carbohydrate and fat intake affect lifespan, metabolism and reproduction in mice
- Nahum Sonenberg 6 studies Co-discovered the mRNA cap-binding protein eIF4E and the 4E-BP proteins that restrain it, and showed how mTOR releases this brake to control protein synthesis
- Hangyul Song 1 study Researcher in Chang-Myung Oh's lab at GIST who tested urolithin A, a gut-microbe product, in mice with a stiff-heart form of heart failure
- Annika G. Sonntag 2 studies Experimental researcher in the Thedieck group who contributed cell data to the dynamic mTOR network model and the AMPK–mTOR amino acid study.
- Breanne Sparta 1 study Quantitative cell biologist who trained in John Albeck's lab at UC Davis, where live single-cell imaging showed that the mTORC1-TFEB signalling axis tracks nutrients and growth factors continuously, and then moved to UCLA as a postdoctoral fellow
- Patricia Spilman 1 study Neuroscientist who showed, with Veronica Galvan, that long-term rapamycin prevents memory loss in an Alzheimer's mouse model, and who later worked with Dale Bredesen on Alzheimer's drug discovery
- Eric Spooner 2 studies Manager of the Whitehead Institute's Proteomics Core Facility, whose mass spectrometry work identified proteins in complexes for many Whitehead studies, including two on amino acid sensing upstream of mTORC1
- Shrivani Sriskanthadevan-Pirahas 1 study Fruit fly biologist in Savraj Grewal's Calgary lab who studies how growth signals and mitochondria in one tissue control how fast the whole larva grows
- Julie St-Pierre 2 studies Biochemist and Vice-President, Research and Innovation at the University of Ottawa who studies how cancer cells adapt their metabolism, and a co-author on McGill work linking mTORC1 to mitochondria and to rapamycin-induced fatty liver
- Taras Stasyk 2 studies Protein chemist in Lukas Huber's group in Innsbruck who has spent two decades applying proteomics to the late endosomes and lysosomes where mTORC1 is controlled
- Darren E Stewart 1 study First author of the 2026 GeroScience registry study of rapamycin and survival in kidney transplant recipients.
- Trevor N Stitt 2 studies Regeneron scientist who worked in David Glass and George Yancopoulos's muscle program on the 2001 papers showing that the Akt/mTOR pathway drives muscle growth and protects against muscle wasting
- Hugo Stocker 1 study Drosophila geneticist who worked for nearly two decades in Ernst Hafen's group in Zurich and helped show how insulin and TOR signalling set cell and body size in the fruit fly, including the discovery that Rheb is essential for TOR-S6K driven growth
- Björn Stork 1 study Heisenberg Professor for the molecular biology of cellular stress responses at Heinrich Heine University Düsseldorf, who studies the ULK1 complex, the switch that starts autophagy, and how it is wired to the energy sensor AMPK and to mTOR
- Daniele Stracka 2 studies Co-author of two studies from Michael Hall's laboratory in Basel that placed mTORC2, the second mTOR complex, at the ribosome and at contact sites between the endoplasmic reticulum and mitochondria
- Randy Strong 12 studies Leads the San Antonio site of the NIA Interventions Testing Program, which tests each compound in parallel at three sites under one shared protocol. He first-authored the program's reports on resveratrol and other supplements (2012) and on rapamycin combined with acarbose (2022)
- Edward Stuttfeld 2 studies Structural biologist who led the 2018 eLife study that gave the first detailed picture of the human mTORC2 core complex, working in Timm Maier's lab in Basel
- Bing Su 4 studies Immunologist who studies how mTOR and MAPK signaling shape immune regulation and vascular function, and senior author of the study showing that SIN1 is a core part of mTORC2.
- Ming-Yuan Su 1 study Structural biologist who solved cryo-EM structures of lysosomal complexes in James Hurley's lab at UC Berkeley and now leads cryo-EM studies of mTORC1 regulators as corresponding author at the Southern University of Science and Technology in Shenzhen
- Yanhong Su 1 study Cardiologist in Tianjin and Cangzhou who studied how a long non-coding RNA drives necroptotic heart-cell death after a blocked artery is reopened
- Liangbo Sun 1 study Researcher studying phosphorylation-based control of autophagy initiation and its role in metabolic liver disease
- Xiaoge Sun 1 study Senior author of a 2026 study showing that the recurrent PIK3CA-E545K mutation drives cervical cancer growth and invasion through AKT/mTOR signalling
- Xiaojie Sun 1 study Contributed to a 2026 toxicology study linking early-life exposure to microplastics and the plasticiser DEHP to autism-relevant brain changes through impaired mTOR-regulated autophagy
- Zexing Sun 1 study Hematology researcher in Hangzhou who studies treatment of bone-marrow failure, including the use of sirolimus (rapamycin) in pure red cell aplasia
- Giulio Superti-Furga 1 study Systems biologist who maps how proteins and drugs interact in cells, with a focus on solute carrier (SLC) membrane transporters; his group helped identify SLC38A9 as a lysosomal amino-acid sensor for mTORC1.
- Chikako Suzuki 1 study Structural biologist from Gerhard Wagner's Harvard lab who showed how the tumour suppressor PDCD4 grabs the helicase eIF4A to block the start of protein synthesis
- Akanksha Swarup 1 study PhD candidate in Timothy Bolger's lab at the University of Georgia who studies how cancer mutations in the RNA helicase DDX3X change the cell's protein-making response to stress
- Angelia Szwed 1 study Lead author, from Estela Jacinto's Rutgers lab, of a long Physiological Reviews article on how the two mTOR complexes are controlled and what they do in metabolism
T
- George Talbott 2 studies Research assistant in Brendan Manning's mTOR lab at Harvard in 2013 and 2014, who contributed to studies on where the TSC complex sits in the cell and how metformin reaches mTORC1
- Fuyuhiko Tamanoi 1 study Biochemist who studied protein farnesylation and the Rheb–TOR pathway in fission yeast and mammalian cells; senior author of the study that found activating mTOR mutations in human cancer data
- Bo Tang 1 study Urology researcher at West China Hospital and first author of a study explaining how kidney cancers escape mTOR inhibitor drugs, and how blocking NEK7 restores their effect
- Shao-Jun Tang 1 study Neuroscientist who, as a postdoc in Erin Schuman's group at Caltech, helped show that a rapamycin-sensitive mTOR pathway is needed for the protein-synthesis-dependent late phase of hippocampal LTP; his lab now studies chronic pain.
- Jiajie Tao 1 study Fish nutrition researcher at Shanghai Ocean University who studies why carnivorous farmed fish such as largemouth bass handle dietary carbohydrate poorly and how this links to mTOR signalling in the liver
- Suzette Tardif 3 studies Primate biologist who spent more than 30 years developing the common marmoset as a research model, and who led the first studies of rapamycin dosing and safety in this small monkey
- Nektarios Tavernarakis 1 study Geneticist who uses the roundworm C. elegans to study how ageing, neurodegeneration, necrotic cell death, autophagy and protein turnover are controlled
- Andrew R. Tee 3 studies First author of one of several 2003 papers showing that the TSC1–TSC2 complex acts as a GTPase-activating protein for Rheb
- Aurelio A. Teleman 5 studies Uses fruit-fly genetics and human cells to study how growth signalling through TOR controls cell and body size. His lab showed that starvation and other stresses move TSC2 to the lysosome to switch mTORC1 off
- Paul Tempst 5 studies Developed mass-spectrometry methods for identifying proteins from tiny samples, and led the Memorial Sloan Kettering proteomics laboratory that identified the unknown partners of mTOR in the raptor, mLST8 and rictor purifications
- Kathrin Thedieck 3 studies Senior author of three Atlas studies that treat mTOR signalling as a dynamic network: TSC-independent mTORC2 activation, concurrent AMPK and mTOR activation by amino acids, and G3BP tethering of TSC to lysosomes.
- Ashley M. Thelen 2 studies Cell biologist who did graduate work in Roberto Zoncu's lysosome lab at UC Berkeley, first author of a 2017 review on the lysosome's roles in lipid metabolism, and later a postdoctoral scholar in Philip Greenberg's lab at Fred Hutch
- George Thomas 14 studies Purified and cloned S6K1, the kinase that became the classic readout of mTORC1 activity. His lab later showed that mice lacking S6K1 resist diet-induced obesity, and that amino acids signal to mTORC1 through the lipid kinase hVps34 (GUL2008)
- Craig B. Thompson 1 study Cancer biologist whose lab studies how growth signals control the uptake and use of nutrients; senior author of the study that described an AMPK- and p53-dependent glucose checkpoint in the cell cycle
- Carson C. Thoreen 7 studies Used Torin1, one of the first ATP-competitive mTOR inhibitors, to reveal functions of mTORC1 that rapamycin cannot block. He then showed that mTORC1 controls translation of mRNAs for the protein-making machinery mainly through the 4E-BP proteins
- Andrew M. Tidball 1 study Stem-cell neuroscientist who builds human neuron and organoid models to find the genes behind brain malformations
- Ashutosh Tiwari 1 study Cancer biologist in Anindya Bagchi's lab who found that a tiny protein made from the circular RNA circPVT1 keeps MYC levels high through mTORC1
- Chiharu Tokunaga 2 studies Member of Kazuyoshi Yonezawa's Kobe team that co-discovered raptor, and first author of a 2004 review on how mTOR combines amino acid and energy signals
- Manoj Tongra 1 study Chief Scientific Officer of Celagenex Research in Mumbai, senior author of reviews and animal studies that link the PI3K/Akt/mTOR pathway to brain and immune disorders
- Sharon A. Tooze 1 study Cell biologist who studies how autophagosomes are built in mammalian cells; her lab has identified several mammalian Atg proteins and helped show that ULK1 is needed for starvation-induced autophagy.
- Bruce C. Trapnell 1 study Pulmonologist-scientist who directs the Rare Lung Diseases Clinical Research Consortium whose MILES trial led to approval of sirolimus for lymphangioleiomyomatosis (LAM); also known for work on pulmonary alveolar proteinosis.
- Hitesha Trivedi 1 study First author of a 2026 PRISMA-guided systematic review of senolytic, senomorphic and anti-ageing drug trials in humans.
- Peter T. Tsai 2 studies Child neurologist and neuroscientist who studies how the cerebellum contributes to autism; first author of the mouse study showing that loss of Tsc1 in Purkinje cells causes autism-like behaviour that rapamycin can prevent.
- Zhi-Yang Tsun 2 studies Biologist who, as first author in David Sabatini's lab, showed that the tumour suppressor folliculin is a GAP for the RagC and RagD GTPases that carry the amino acid signal to mTORC1
- Benjamin E. Turk 2 studies Kinase biochemist who studies how protein kinases choose their substrates; co-author on the discovery that AMPK phosphorylates raptor and on the study showing that mTORC1 sites differ in intrinsic substrate quality.
- Marc Turner 2 studies Research assistant and lab manager in Brendan Manning's mTOR lab at Harvard from 2014 to 2016, who contributed to studies on nucleotide synthesis in tumour cells and on metformin's route to mTORC1
U
- Shinsuke Uda 2 studies Systems biologist who uses information theory and modelling. He co-authored the studies showing that the insulin–AKT pathway encodes insulin’s timing pattern, and that S6K, downstream of mTORC1, reads only the fast, pulse-like part.
- Beatrix M. Ueberheide 1 study Mass spectrometry and proteomics specialist who directs NYU's proteomics core and contributed the protein profiling to the Down syndrome hippocampus mTOR study.
- Halvor Ullern 1 study Researcher in Helene Knævelsrud's autophagy group at the University of Oslo and first author of a 2026 study of folliculin loss in Birt-Hogg-Dubé kidney cancer
- Sung Hee Um 1 study Molecular biologist at Sungkyunkwan University School of Medicine whose work centres on the S6 kinases, and first author of the 2004 Nature study showing that mice without S6K1 resist obesity
- Silvan R. Urfer 1 study Veterinarian and epidemiologist of aging at the University of Washington who led the first placebo-controlled rapamycin trial in pet dogs, an early step of the Dog Aging Project
V
- Max L. Valenstein 3 studies First author of the cryo-EM structures of GATOR2, the hub that tells mTORC1 whether amino acids are present, alone and bound to the sensors Sestrin2 and CASTOR1
- Alexander J. Valvezan 4 studies Showed as a Manning-lab postdoc that mTORC1 matches nucleotide production to demand, creating a weak point that can be targeted in tumours with TSC loss. His Rutgers lab found that mTORC1 activity rises and falls through the cell cycle and helps drive entry into mitosis
- Nikkhil Velingkaar 1 study Postdoctoral fellow studying how the circadian clock times caloric restriction's effects on liver mTOR signaling and metabolism
- Tibor Vellai 1 study Hungarian geneticist who showed in 2003 that silencing the TOR gene roughly doubles the lifespan of the worm C. elegans, and who studies autophagy and ageing in worms at Eötvös Loránd University in Budapest
- Elodie Villa 2 studies First author of the study showing that mTORC1 raises production of the methyl donor SAM through MAT2A and boosts m6A mRNA methylation to support protein synthesis and cell growth.
- Benoit Viollet 4 studies Showed that metformin still lowers liver glucose production without AMPK or LKB1, pointing instead to a drop in cellular energy charge
- Claudio De Virgilio 3 studies Yeast geneticist whose lab found the EGO/Rag GTPase complex that activates TORC1 and showed that the SEACIT complex (Iml1–Npr2–Npr3) switches TORC1 off by acting as a GAP for the Rag GTPase Gtr1.
- Kristian Kjær Vissing 1 study Studies the control of protein balance in skeletal muscle and how this knowledge might counter muscle loss.
- Sofia Helena Vitte 1 study Brazilian medical researcher who works on evidence synthesis and cardiometabolic studies, and first author of the 2026 meta-analysis of everolimus in heart transplant recipients
- Petrus J. de Vries 2 studies Child and adolescent psychiatrist at the University of Cape Town known for work on TAND, the behavioural, learning and mental-health problems of tuberous sclerosis complex, and co-author of major everolimus trials in TSC
W
- Nikhil Wagle 1 study Medical oncologist and cancer genomics researcher at Dana-Farber who studies why some patients respond exceptionally well to targeted drugs, including a patient whose tumour carried two activating MTOR mutations
- Adam T. Waickman 2 studies Immunologist who trained in Jonathan Powell's mTOR and T cell lab at Johns Hopkins and now studies human immune responses to dengue virus at SUNY Upstate Medical University
- Cheryl Lyn Walker 1 study Cancer biologist and toxicologist who studies how environmental exposures reprogram the epigenome and target tumour suppressor genes; senior author of the study linking ATM to TSC2 and mTORC1 in the response to oxidative stress
- Thomas Walter 1 study Medical oncologist in Lyon who specialises in neuroendocrine tumours and led the COMPETE phase 3 trial comparing 177Lu-edotreotide with everolimus
- Thierry Walzer 1 study Studies how natural killer (NK) cells develop and become active; his team showed in mice that IL-15 signalling through mTOR is needed for NK-cell maturation and activation.
- Jie Wang 1 study Corresponding author of a 2026 JACS paper identifying PKM2 as a direct methionine-sensing protein that signals into mTORC1 via GATOR2.
- Jing Wang 1 study Showed as first author that the CORVET/HOPS trafficking machinery is needed for T cells to sense amino acids and activate mTORC1
- Qing Wang 1 study Cancer biologist in Hsin-Sheng Yang's lab at the University of Kentucky who studies how the tumour suppressor Pdcd4 holds back mTORC2 signalling, protein synthesis and cancer cell invasion
- Rong Wang 1 study Researcher in Viviana Pérez's group at the Linus Pauling Institute who studied how rapamycin holds back cellular senescence, and first author of work separating its effect on the senescence secretory profile from its Nrf2-dependent effect on cell-cycle arrest
- Ruizhao Wang 1 study Built FPTT, fluorescent 'ticker tapes' that record several signalling pathways in living cells over days, and used its mTOR version to follow mTOR activity oscillating through the cell cycle
- Ruoning Wang 1 study Showed as first author, in Douglas Green's lab, that the transcription factor Myc drives the metabolic switch of activated T cells, and now leads an immunometabolism lab
- Shuyu Wang 2 studies Co-discovered SLC38A9 as a Sabatini-lab MD-PhD student, a lysosomal amino-acid transporter that signals arginine sufficiency to mTORC1
- Siming Wang 1 study Member of Daqing Zhao's natural-products group who contributed to a study showing that a Chinese yam extract restores mTOR–Beclin-1-regulated autophagy in ageing testis cells
- Tim Wang 5 studies Co-developed genome-wide CRISPR screening in human cells (reported in parallel by Feng Zhang's lab) as a graduate student with David Sabatini and Eric Lander, and contributed to studies showing that the 4E-BPs mediate mTORC1's control of translation and that CASTOR1 senses arginine
- Yifei Wang 1 study Environmental toxicologist who contributed to a study of how early-life exposure to food-contact microplastics and a common plasticiser disrupts brain development through mTOR signalling
- Yunwei Wang 1 study Burn and wound-repair researcher who contributed to a study testing the plant flavonoid dihydromyricetin as an anti-scarring treatment
- Zhenhai Wang 1 study Neurologist in Yinchuan who leads cell studies of microglia, the brain's immune cells, and of how Brucella bacteria survive inside them
- Wenyi Wei 1 study Studies how protein stability and cell signalling, including the PI3K-mTOR-AKT network, are controlled in cancer cells.
- Thomas Weichhart 1 study Immunologist who showed that mTOR sets the tone of the innate immune response, and now studies how macrophage metabolism drives granulomatous disease
- Vicky H Whittemore 1 study Neuroscientist and NIH program director for epilepsy and ME/CFS research who spent over two decades working for patient organisations, including the Tuberous Sclerosis Alliance
- Sabine Wilhelm 3 studies Co-author on two Demetriades-lab studies of amino acid sensing by mTORC1: the Rag GTPase dimer code and the spatial split of mTORC1 signalling.
- John E Wilkinson 1 study Pathologist at the University of Michigan who examines animal tissues for aging and cancer studies, and first author of the 2012 paper showing that rapamycin slows many signs of aging in mice
- Roger L. Williams 2 studies Solved structures showing how the Rag GTPases bind mTORC1 and how TOR forms a dimer, working at the MRC Laboratory of Molecular Biology
- Dominic Winter 1 study Proteomics researcher who uses mass spectrometry to map lysosomal proteins and their modifications, including phosphorylation, in health and disease.
- Dominic J. Withers 1 study Studies how hormone and nutrient signaling pathways control metabolism and ageing, including the finding that loss of S6K1 extends lifespan in mice.
- Rachel L. Wolfson 8 studies Identified Sestrin2 as the direct leucine sensor of the mTORC1 pathway as a Sabatini-lab MD-PhD student. She also co-discovered KICSTOR, the complex that recruits GATOR1 to the lysosome
- Michael Wong 1 study Pediatric epileptologist whose lab studies how epilepsy develops, with a focus on mTOR in tuberous sclerosis complex and brain injury; senior author of the mouse study in which rapamycin prevented epilepsy in a TSC model.
- Dianqing (Dan) Wu 1 study Signalling biologist who studies Wnt signalling and receptor-driven cell migration, and who showed that PIP3 can directly stimulate mTORC2 kinase activity.
- J. Julie Wu 1 study Researcher in Toren Finkel's laboratory at the US National Heart, Lung, and Blood Institute and first author of the 2013 study showing that mice making only a quarter of the normal amount of mTOR live about 20 percent longer
- Stephan Wullschleger 1 study Biochemist trained in Michael Hall's Basel lab on TOR complex 2 in yeast, and first author of the widely cited 2006 Cell review that laid out the two TOR complexes and what each controls
- Gregory A. Wyant 5 studies Showed that the lysosomal protein SLC38A9 exports leucine and other essential amino acids out of the lysosome, letting cells grow on proteins they have taken up and broken down there
X
- Tianxiong Xiao 1 study Researcher at the Hangzhou Institute for Advanced Study and first author of a 2026 review on how nutrient-sensing pathways steer adult stem cells through life
- Yulian Xiao 1 study Contributed to a study identifying a tRNA fragment (tRF-17-8SPOL52) that drives bortezomib resistance in multiple myeloma by activating autophagy
- Jiayuan Xie 1 study Animal nutrition researcher in Ning Jiao's group at Shandong Agricultural University who studies how feed contaminants damage the pig gut, and first author of the piglet study on glutamine and bisphenol A
- Cong Xu 1 study Hematologist in Shenzhen who studies drug resistance and drug safety in multiple myeloma, and senior author of a study linking a small RNA fragment to autophagy-driven resistance to bortezomib
- Jingting Xu 1 study Researcher in the orthopedics department of Tongji Hospital, Wuhan, and first author of a 2026 review on mTORC2 and its partner RICTOR in immune cells and inflammatory disease
- Tian Xu 1 study Drosophila geneticist whose Yale lab helped show that Akt controls growth by phosphorylating the tumour suppressor Tsc2, linking the insulin pathway to TSC
- Yanhui Xu 1 study Structural biologist whose Fudan lab solved a cryo-EM structure of human mTORC2 in 2018, showing how rictor and mSin1 block rapamycin's access to mTOR
- Yulang Xu 1 study Paediatric surgeon-researcher who led a multicentre study showing that head-and-neck kaposiform hemangioendothelioma responds especially well to the mTOR inhibitor sirolimus
Y
- Michael B. Yaffe 2 studies Cancer biologist and physician-scientist known for working out how phosphorylation creates binding sites on proteins, including the 14-3-3 family of phosphoserine/threonine-binding proteins, and how kinases choose their targets.
- George D. Yancopoulos 2 studies Industry scientist who co-founded Regeneron and led drug discovery there; in this Atlas he is senior author of an early paper showing that Akt/mTOR signalling controls muscle size.
- Ge Yang 1 study Researcher in Rui Li's group at Central China Normal University who has led mouse studies on how microplastics, nanoplastics and the plasticiser DEHP affect the young brain
- Haijuan Yang 2 studies Solved, as first author in the Pavletich lab, the crystal structure of the mTOR kinase and the structure of mTORC1 activated by RHEB
- Hsin-Sheng Yang 1 study Studies translational control of genes that drive tumour invasion and metastasis, centred on the tumour suppressor Pdcd4
- Hyo J Yang 2 studies Researcher in Nikola Pavletich's structural biology laboratory at Memorial Sloan Kettering and co-author of the two Nature papers that showed the atomic structure of mTOR and of mTORC1
- Juan Yang 1 study Contributed to a study showing that the Brucella suis vaccine strain S2 drives macrophage polarisation and autophagy through PI3K/Akt/mTOR signalling to survive inside cells
- Jun Yang 1 study Contributed to a study showing that pungenin promotes hair growth in mouse models of androgenic alopecia through the PI3K/AKT/mTOR pathway
- Qian Yang 1 study Researcher in Kun-Liang Guan's Michigan lab and first author of the 2006 study that identified Sin1 as an essential part of mTOR complex 2
- Xiaoming Yang 1 study Showed as senior author that the liver-secreted protein hepassocin protects against age-related liver senescence and helps the liver regenerate
- Yang Yang 1 study Showed as first author that the liver-secreted protein hepassocin protects against age-related liver senescence and helps the liver regenerate
- Yu Chi Yang 2 studies Scientist at Revolution Medicines who worked on the company's bi-steric mTORC1-selective inhibitors, from the breast cancer lab studies of RMC-6272 to the first trial of RMC-5552 in patients
- James C. Yao 1 study Medical oncologist at MD Anderson Cancer Center who led the RADIANT-3 and RADIANT-4 trials that made the mTOR inhibitor everolimus a standard treatment for advanced neuroendocrine tumours
- Chih-Ko Yeh 1 study Professor of Comprehensive Dentistry at UT Health San Antonio who studies how ageing changes saliva and the salivary glands, and how damaged glands might be repaired
- Ömer H. Yilmaz 1 study Pathologist and stem-cell biologist who studies how diet and nutrient sensing control intestinal stem cells; as a postdoc with David Sabatini he showed that calorie restriction acts on the stem-cell niche through mTORC1 in Paneth cells
- Jian Yin 1 study Structural biologist at Tsinghua University who used cryo-electron microscopy to show how the human amino acid transporter PAT1 (SLC36A1) recognises and moves its cargo
- Calvin K. Yip 1 study Structural biologist who uses electron microscopy to study large protein machines; as a postdoc at Harvard Medical School he determined a cryo-EM structure of human mTORC1, and his lab now studies the autophagy machinery.
- Kazuyoshi Yonezawa 5 studies Led the Kobe University group that co-discovered raptor in 2002, in parallel with the Sabatini lab. His team then showed that raptor binds mTOR's substrates through their TOS motif and that PRAS40 is itself an mTORC1 substrate
- Hongbo You 1 study Orthopedic researcher at Tongji Hospital, Wuhan, and senior author of a 2026 mouse study showing that the plant compound corilagin slows osteoarthritis by restoring cartilage-cell autophagy
- Lisa Young 2 studies Lung physician-scientist who helped run the first sirolimus trials in lymphangioleiomyomatosis (LAM) and now leads pulmonary medicine at the Children's Hospital of Philadelphia
- Jiafeng Yu 1 study Anesthesiology researcher at Tianjin Medical University General Hospital and first author of a mouse study showing that breathing hydrogen gas protects memory after sepsis by calming mTOR in brain support cells
- Ker Yu 1 study Last author of the 2010 Journal of Biological Chemistry study on mTOR, Maf1 and RNA polymerase III transcription.
- Li Yu 1 study Cell biologist at Tsinghua University who, as a postdoc at the NIH, found how cells end autophagy and rebuild their lysosomes, and whose own group later discovered the migrasome, a new organelle left behind by migrating cells
- Shiting Yu 1 study Natural-products researcher who contributed to a study showing that a Chinese yam (Dioscorea polystachya) extract counters male reproductive ageing through the mTOR–Beclin-1 autophagy axis
- Shuai Yu 1 study Neurology researcher who contributed to a study showing that the lipid kinase PIP4K2A protects the brain after ischaemic stroke by relieving a block on autophagy and boosting AKT/mTOR signalling
- Xiang Yu 1 study Member of Yanfeng Hu's gastric-cancer lab who contributed to a study showing how a microbiota-linked metabolite, kynurenic acid, drives resistance to PD-1 blockade
- Xiaotian Yu 1 study Stroke neurology researcher who contributed to a study of how PIP4K2A limits brain injury after ischaemia and reperfusion through the TRIB3–p62 and AKT–mTOR pathways
- Yang Yu 1 study Anesthesiologist and researcher at Tianjin Medical University General Hospital who studies hydrogen gas as a treatment for sepsis and its brain damage, and co-senior author of the 2026 study linking hydrogen, mTOR and myelin repair
- Yonghao Yu 1 study Used phosphoproteomics to show that mTORC1 phosphorylates and stabilises Grb10, which then acts as a feedback brake on insulin and IGF-1 signalling
- Elizabeth D. Yuan 3 studies Second author on the study showing that S6K1 phosphorylates BMAL1 to link mTOR signalling with circadian protein synthesis, and co-author on the follow-up in tuberous sclerosis models.
Z
- Sajad Zalzala 1 study Family physician who co-founded AgelessRx and, as senior author, co-led PEARL, a year-long randomised trial of low-dose intermittent rapamycin in healthy older adults
- Nicola Zamboni 2 studies Group leader at ETH Zurich's Institute of Molecular Systems Biology who develops mass spectrometry methods to measure hundreds of metabolites at once, used in many collaborations on cell metabolism
- Alex Zaufel 1 study Researcher studying bile acid metabolism and mTORC1 signaling in liver disease
- Hu Zeng 1 study Immunologist at Mayo Clinic who studies how mTOR signalling and cell metabolism shape T cells in autoimmunity, and who showed as a postdoc that regulatory T cells need mTORC1 to work
- Ling-Hui Zeng 1 study Pharmacologist who studies mTOR signalling in epilepsy; as a researcher in Michael Wong's group she was first author of the mouse study showing that rapamycin prevents epilepsy in a tuberous sclerosis model.
- Thomas von Zglinicki 2 studies Cell-senescence researcher who co-authored the Newcastle studies on stuck-on mTORC1 in senescent cells and on loss of basal mitophagy as a driver of cellular ageing.
- Wencai Zhai 1 study Researcher at Yantai University and first author of a mouse study showing that the plant compound pungenin speeds hair regrowth in hormone-driven hair loss
- Zongzhao Zhai 1 study Senior author of a 2026 Nature study identifying Lsp2 as a rapamycin-resistant mTORC1 effector that extends lifespan in Drosophila when removed
- Chen Zhang 1 study Ran the liver-specific Tsc1-knockout mouse study showing that non-canonical mTORC1–TFEB activation drives hepatocyte plasticity and aggressive liver cancer
- Chunting Zhang 1 study Contributed to a study showing that the lncRNA LINP1 protects irradiated skin cells from senescence by disrupting the mTOR–p53 interaction
- Jin Zhang 1 study Builds fluorescent biosensors that show where and when signalling enzymes are active inside living cells; senior author of TORCAR, an early live-cell reporter of mTORC1
- Jingyue Zhang 1 study Pharmacy researcher at Lanzhou University working with Wen Li on the chemistry and actions of traditional Chinese medicines, from extracting plant compounds to testing a herbal formula in breast cancer models
- Jun Zhang 1 study Cardiologist at Cangzhou Central Hospital, a teaching hospital of Tianjin Medical University, and senior author of a study on RNA-driven heart-cell death after reperfusion
- Lei Zhang 1 study Contributed to a 2026 mouse study showing that the plant compound pungenin relieves androgenic alopecia through the PI3K/AKT/mTOR pathway
- Ling Zhang 1 study Contributed to a 2026 toxicology study linking early-life exposure to microplastics and the plasticiser DEHP to autism-relevant brain changes through impaired mTOR-regulated autophagy
- Sen Zhang 1 study Contributed to a study showing that largemouth bass have a weak insulin/mTOR/SREBP1 fat-making pathway, so excess dietary carbohydrate is stored as liver glycogen rather than fat
- Susu Zhang 1 study Contributed to a study showing that salvianolic acid B improves motor recovery after spinal cord injury in association with AKT/mTOR/HIF-1α activation and blood-vessel growth
- Xiaoxiao Zhang 1 study Eye specialist at Guangzhou Aier Eye Hospital who works on childhood myopia, from school screening and myopia-control lenses to the biology of the sclera in animal models
- Xiaoyan Zhang 1 study Nephrologist at Zhongshan Hospital, Fudan University, and senior author of a 2026 study linking the enzyme USP7 to mTOR activation and kidney scarring
- Yiwen Zhang 1 study Researcher at Changchun University of Chinese Medicine who contributed to a study showing that a Chinese yam extract counters male reproductive ageing through mTOR–Beclin-1 autophagy
- Yukun Zhang 1 study Senior author of a study showing that failing chaperone-mediated autophagy lets midnolin accumulate and degrade TSC2, overactivating mTORC1 and accelerating intervertebral disc degeneration
- Jiaqi Zhao 1 study Co-author; chemical biologist who helped build a chemical probe revealing a glycolytic enzyme's secret second job as a methionine sensor for mTORC1.
- Joy Zhao 1 study Researcher in Sean Cregan's lab studying how chronic cell-stress signalling through ATF4 suppresses mTOR and kills dopamine neurons in Parkinson's disease models
- Pan Zheng 2 studies Showed as senior author that blood stem cells need TSC to keep mTOR in check in order to stay dormant, and that rapamycin restores the function of aged blood stem cells in mice
- Qiangsun Zheng 1 study Cardiologist at the Second Affiliated Hospital of Xi'an Jiaotong University whose group studies atrial fibrillation as a disorder of heart metabolism, in mice and in patients
- Jiangyuan Zhou 1 study Member of Yi Ji's pediatric vascular-anomalies and surgical-oncology team; co-author on the sirolimus-for-Kaposiform-hemangioendothelioma study.
- Jing Zhou 1 study Researcher in Luis Parada's lab whose work includes the 2009 study showing that rapamycin prevents and reverses brain abnormalities in neural Pten-knockout mice
- Nan Zhou 1 study Oncology researcher at the First Affiliated Hospital of Harbin Medical University and first author of a 2026 study linking a DNA-demethylating enzyme to PI3K-AKT-mTOR activation in lung adenocarcinoma
- Ruijia Zhou 1 study Researcher in the orthopedics department of Tongji Hospital, Wuhan, and first author of a 2026 study on corilagin, a plant polyphenol that protected mouse cartilage by restoring autophagy
- Xin Zhou 1 study Built TORCAR, an early genetically encoded FRET reporter that lets mTORC1 activity be watched in living cells
- Lifu Zhu 1 study Environmental health researcher at Anhui Medical University and first author of a 2026 mouse study on how the solvent trichloroethylene damages the liver when the LKB1/AMPK energy sensor is missing
- Brian M. Zid 1 study Biochemist at UC San Diego who studies how cells decide which messenger RNAs to translate under stress, and who showed as a Caltech student that the mTOR target 4E-BP is needed for dietary restriction to lengthen fly lifespan
- Vittoria Zinzalla 1 study Cell biologist who, in Michael Hall's Basel lab, found that mTORC2 is switched on by binding to ribosomes, and later moved to cancer pharmacology at Boehringer Ingelheim in Vienna
- Roberto Zoncu 14 studies Showed as a postdoc that mTORC1 senses amino acids from inside the lysosome, through the v-ATPase and Ragulator. His Berkeley lab has since mapped how the Rag GTPases and the folliculin complex switch mTORC1 on, and how lysosomal cholesterol feeds into the same system
- Yang Zong 1 study Pathologist at the University of Wisconsin-Madison who works on the diagnosis of kidney and genitourinary tumours, senior author of a 2026 study proposing GPR143 as a marker for kidney tumours driven by the FLCN/TSC/mTOR-TFE pathway
Was this page useful?
Thank you. Your answer was counted anonymously.